<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Emergency contraception</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Emergency contraception</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Emergency contraception</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David Turok, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Courtney A Schreiber, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen Eckler, MD, FACOG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 28, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3019487816"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Emergency contraception (EC) refers to the contraceptive options that can decrease the risk of pregnancy after intercourse but before the establishment of a pregnancy. These methods can be used after intercourse when no contraception was employed (ie, unprotected intercourse [UPI]), a method was used imperfectly (ie, a condom slipped or broke, pills or injection were missed), or sex was forced without use of contraception. Clinicians should be able to educate patients about the multiple methods and ensure availability. EC can be offered to heterosexually active patients of all ages.</p><p>This topic will review the patient selection, counseling, and administration of EC. Related content on the general selection of contraception is presented elsewhere. (See  <a class="medical medical_review" href="/d/html/5459.html" rel="external">"Contraception: Counseling and selection"</a>.)</p><p>In this topic, we will use the terms "woman/en" or "patient(s)" as they are used in the studies presented. However, we recognize that not all people who seek emergency contraception identify as women and we encourage the reader to consider the specific counseling needs of transgender and gender diverse individuals.</p><p class="headingAnchor" id="H3929058864"><span class="h1">WHAT IS EMERGENCY CONTRACEPTION AND HOW DOES IT WORK?</span></p><p class="headingAnchor" id="H2303568373"><span class="h2">Emergency contraception for prevention of pregnancy</span><span class="headingEndMark"> — </span>EC refers to products that prevent pregnancy from occurring after an episode of unprotected intercourse (UPI). EC methods include oral medication and intrauterine devices (IUDs). UPI can be a result of contraception non-use or imperfect use or can result from forced sexual activity. EC does not interrupt an existing pregnancy; thus, it does <strong>not</strong> cause abortion.</p><p>EC must be initiated within a specific time frame from UPI in order to be effective; the time intervals vary by product  (<a class="graphic graphic_algorithm graphicRef130902" href="/d/graphic/130902.html" rel="external">algorithm 1</a>). It is not meant to be used as a regular contraceptive method but as a secondary method in the scenarios discussed previously. There are products dedicated to EC use and contraceptive methods, like the intrauterine devices and combined oral pills, that are used off-label for EC. All of these products are legal throughout the United States. (See <a class="local">'What are the emergency contraception methods?'</a> below.)</p><p class="headingAnchor" id="H2285147330"><span class="h2">Mechanisms of action</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral medication EC methods</strong> – Rigorous, meticulously executed studies have demonstrated that oral <a class="drug drug_general" data-topicid="15626" href="/d/drug information/15626.html" rel="external">ulipristal</a> acetate (UPA) and <a class="drug drug_general" data-topicid="104542" href="/d/drug information/104542.html" rel="external">levonorgestrel</a> (LNG) EC regimens prevent ovulation [<a href="#rid1">1,2</a>]. To be perfectly clear, oral EC <strong>is not</strong> an abortifacient, and this is very well understood. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>LNG</strong> – LNG prevents ovulation if taken in the pre-ovulatory period by blocking the luteinizing hormone (LH) surge, thus inhibiting follicular development and egg release [<a href="#rid3">3</a>]. In December 2022, the U.S. Food and Drug Administration (FDA) changed the label for oral <a class="drug drug_general" data-topicid="104542" href="/d/drug information/104542.html" rel="external">levonorgestrel</a> 1.5 mg tablets (commercial name Plan B One-Step) and removed prior language suggesting that there may be a postovulatory (eg, a postfertilization or implantation) effect [<a href="#rid2">2,4</a>]. The Consumer Information Leaflet now clearly states that the drug works by inhibiting or delaying ovulation and through midcycle hormonal changes.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>UPA</strong> – UPA delays ovulation in both the pre-ovulatory period and after the LH surge has started [<a href="#rid1">1,5</a>]. This extended period of activity may explain UPA's greater efficacy in preventing pregnancy compared with oral LNG. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10263" href="/d/drug information/10263.html" rel="external">Mifepristone</a> – Low-dose mifepristone (available outside of the United States) also prevents ovulation; it binds to <a class="drug drug_general" data-topicid="9817" href="/d/drug information/9817.html" rel="external">progesterone</a> receptors to block progesterone's effects [<a href="#rid6">6</a>]. Mifepristone may also disrupt luteal phase events and endometrial development [<a href="#rid7">7</a>]. </p><p></p><p class="bulletIndent1">Neither LNG nor UPA prevents ovulation if taken on the day of the LH peak or later, nor do they prevent implantation [<a href="#rid1">1,8,9</a>]. None of these drugs interfere with implantation of a fertilized egg or an established pregnancy [<a href="#rid10">10,11</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>IUDs</strong> – Contrary to the clearly defined mechanisms of action for both oral EC methods, there is no clear description that fully explains the efficacy of the IUDs for EC. While data clearly support inhibition of fertilization as the primary mode of action for copper and <a class="drug drug_general" data-topicid="104541" href="/d/drug information/104541.html" rel="external">levonorgestrel IUDs</a> when they are used continuously, the mechanism for postcoital use is not clear [<a href="#rid12">12</a>]. However, there is no evidence to support a postimplantation effect, and as pregnancy is defined by implantation, these methods are not acting as abortifacients.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Copper 380 mm</strong><strong><sup>2</sup></strong> <strong>IUD</strong> – It is plausible that, just as with routine use where copper particles disrupt sperm and ovum function to prevent union as well as alter physiology in the uterus and fallopian tubes, postcoital copper 380 mm<sup>2</sup> IUD placement may involve these same mechanisms. It is also possible that the exceptional efficacy of copper 380 mm<sup>2</sup> IUDs for EC involves preventing implantation of a fertilized egg [<a href="#rid13">13</a>]. (See  <a class="medical medical_review" href="/d/html/116579.html" rel="external">"Intrauterine contraception: Background and device types", section on 'Copper IUD'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>LNG 52 mg IUD</strong> – In the case of LNG IUDs used for EC, it is unlikely the mechanisms supporting routine use, including development of a progestin-mediated thickening of the cervical mucus, would impact EC efficacy. However, laboratory data support the potential for LNG to directly interfere with sperm transport, sperm capacitation, the acrosome reaction, and oviduct transport [<a href="#rid14">14-17</a>]. Even without synthetic progestogens, clinical data demonstrate EC efficacy not only for copper 380 mm<sup>2</sup> and <a class="drug drug_general" data-topicid="104541" href="/d/drug information/104541.html" rel="external">levonorgestrel IUDs</a>, but also for inert IUDs [<a href="#rid18">18,19</a>]. We lack a clear explanation of the mechanism of action for LNG IUD EC efficacy, and it is likely that a postfertilization effect may contribute to its efficacy in this setting.</p><p></p><p class="headingAnchor" id="H1033305119"><span class="h1">WHAT ARE THE EMERGENCY CONTRACEPTION METHODS?</span><span class="headingEndMark"> — </span>Options for EC include two types of intrauterine devices (IUDs), which are the most effective form of EC, and oral medications. EC methods discussed below and in the table  (<a class="graphic graphic_table graphicRef120627" href="/d/graphic/120627.html" rel="external">table 1</a>) are presented in decreasing order of efficacy.</p><p class="headingAnchor" id="H2111696437"><span class="h2">Intrauterine devices</span><span class="headingEndMark"> — </span>When used for EC, both the copper 380 mm<sup>2</sup> IUD and <a class="drug drug_general" data-topicid="104542" href="/d/drug information/104542.html" rel="external">levonorgestrel</a> (LNG) 52 mg IUD have first-cycle pregnancy rates of less than 1 percent, provide ongoing highly effective contraception, and are well tolerated [<a href="#rid20">20,21</a>]. In the United States, the copper 380 mm<sup>2</sup> IUD is sold under the commercial name Paragard while the LNG 52 mg IUD is available under the commercial names Mirena and Liletta.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Copper 380 mm</strong><strong><sup>2</sup></strong><strong> IUD</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Efficacy</strong> – The copper 380 mm<sup>2</sup> IUD (commercial name Paragard) is the most effective form of EC, with first-cycle pregnancy rates of 0.1 percent [<a href="#rid20">20</a>]. This is based on extensive use summarized in a systematic review including 7034 users from 42 studies. (See <a class="local">'Emergency contraception efficacy'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Insertion and use</strong> – While several guidelines advise the copper 380 mm<sup>2</sup> IUD can be inserted within five days of UPI [<a href="#rid22">22,23</a>], the Society of Obstetricians and Gynaecologists of Canada recommends use within seven days of UPI [<a href="#rid24">24</a>]. If left in place, the device provides at least 10 years of reversible contraception [<a href="#rid25">25</a>]. (See <a class="local">'Initiation and use'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Comparison with oral EC drugs</strong> – The TCu380A reduces the risk of unintended pregnancies over the following year by one-half compared with those using oral LNG for EC [<a href="#rid26">26</a>] and continues to provide highly effective contraception for up to 12 years after insertion [<a href="#rid27">27</a>]. (See <a class="local">'How effective is emergency contraception at preventing pregnancy?'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="104542" href="/d/drug information/104542.html" rel="external">Levonorgestrel</a><strong> 52 mg IUD</strong> – LNG 52 mg IUDs appear to provide effective EC and have the notable advantage that they can be left in place for long-term reversible contraception [<a href="#rid21">21</a>]. The information below applies only to LNG 52 mg IUDs (commercial names Mirena, Liletta); other <a class="drug drug_general" data-topicid="104541" href="/d/drug information/104541.html" rel="external">LNG IUDs</a> with less total LNG have not been studied for EC and should not be used for this purpose [<a href="#rid28">28</a>]. (See <a class="local">'How effective is emergency contraception at preventing pregnancy?'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Efficacy</strong> – EC data for the LNG 52 mg largely comes from a noninferiority trial comparing it with the copper 380 mm<sup>2</sup> IUD that reported unintended pregnancy rates of 0.3 and 0.0 percent, respectively [<a href="#rid21">21</a>]. Pregnancy rates were not statistically different between the two devices, which led to the conclusion that the LNG 52 mg was noninferior to the copper 380 mm<sup>2</sup> IUD for EC. At one year of follow-up, the unintended pregnancy and device discontinuation rates were similar for both groups, with one unintended pregnancy occurring for each IUD type [<a href="#rid29">29</a>]. Device superiority is not yet known.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Insertion and use</strong> – In the initial trial comparing LNG 52 mg with the copper 380 mm<sup>2</sup> IUD, the device was inserted within five days from UPI [<a href="#rid21">21</a>]. It is not yet known if the LNG 52 mg IUDs (commercial names Mirena and Liletta) will provide EC beyond five days from UPI. The LNG 52 mg IUD devices are approved for contraception for eight years of use [<a href="#rid30">30-33</a>]. (See  <a class="medical medical_review" href="/d/html/116579.html" rel="external">"Intrauterine contraception: Background and device types"</a> and  <a class="medical medical_review" href="/d/html/116579.html" rel="external">"Intrauterine contraception: Background and device types", section on 'Duration'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Comparison with other EC methods</strong> – <a class="drug drug_general" data-topicid="104541" href="/d/drug information/104541.html" rel="external">LNG IUDs</a> are often preferred by patients for long-term contraception because of the associated reduction in menstrual bleeding and cramping [<a href="#rid34">34-36</a>]. In addition, LNG 52 mg IUDs can be used by individuals of any body mass, treat heavy menstrual bleeding, and reduce endometriosis-related pelvic pain. (See  <a class="medical medical_review" href="/d/html/116579.html" rel="external">"Intrauterine contraception: Background and device types", section on 'Levonorgestrel IUD'</a>.)</p><p></p><p class="headingAnchor" id="H3110138011"><span class="h2">Oral medication emergency contraception methods</span><span class="headingEndMark"> — </span>Oral EC methods include products specifically marketed for EC and an alternate dosing regimen of oral contraceptive pills that contain both estrogen and a progestin (the Yuzpe method).</p><p class="bulletIndent2"><span class="glyph">•</span><strong>Ulipristal</strong><strong> acetate (UPA)</strong> – UPA is a selective progestin receptor modulator (ie, antiprogestin) that at a dose of 30 mg can be used up to 120 hours (ie, five days) after UPI [<a href="#rid37">37</a>]. Commercial names include ella, ellaOne, and Fibristal. Progestin-containing contraceptives should not be used with UPA or for five days after UPA administration because of concerns that the progestin contraceptive will interfere with UPA action [<a href="#rid37">37,38</a>]. (See <a class="local">'Initiation and use'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Levonorgestrel</strong><strong> (LNG)</strong> – Oral LNG 1.5 mg is licensed for use up to 72 hours after UPI [<a href="#rid39">39</a>], although it is used off-label beyond that time frame with established efficacy up to 120 hours (ie, five days) [<a href="#rid40">40</a>]. In regions where <a class="drug drug_general" data-topicid="9781" href="/d/drug information/9781.html" rel="external">piroxicam</a> is readily available and low cost, clinicians may prescribe oral LNG with a single dose of oral piroxicam 40 mg to increase efficacy, although this is not required as supporting data are limited [<a href="#rid41">41</a>]. Oral LNG as a method of EC is available over the counter in pharmacies without a prescription or age restriction. (See <a class="local">'Emergency contraception efficacy'</a> below and <a class="local">'Initiation and use'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mifepristone</strong> – <a class="drug drug_general" data-topicid="10263" href="/d/drug information/10263.html" rel="external">Mifepristone</a>, in doses of 10 to 25 mg, is available in China, Russia, Vietnam, and other locations [<a href="#rid6">6</a>]. It is well studied and effective in this dose range, which is a small fraction of the 200 mg dose used for medication abortion and management of pregnancy loss [<a href="#rid42">42,43</a>]. A 2019 meta-analysis reported it is at least as effective as LNG and more effective than the Yuzpe method [<a href="#rid44">44</a>]. However, mifepristone 10 mg and 25 mg tablets are not available universally (200 mg and 300 mg doses are available in the United States).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Combined oral estrogen and LNG contraceptive pills (Yuzpe method) </strong>– The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.bedsider.org%2Ffeatures%2F88-the-yuzpe-method-effective-emergency-contraception-dating-back-to-the-70s&amp;token=0S1UYpn%2FP0phpQyBKxjL9OygroOq2rcnMiw7V6xylno6DpYM800H8bcU7y%2FM4zm2X6lzoOxDYwkjGlWjdSUSMZlYmOm4IgtrCtI2z7hC91PafjMqmXzIuQxoBU2me0loSMoYl3TsUPl6ebG7p8SFwQ%3D%3D&amp;TOPIC_ID=5475" target="_blank">Yuzpe method</a> can be an effective alternative when combined hormonal contraceptives using 100 mcg of ethinyl estradiol and 0.5 mg of LNG (or the equivalent) are available. Repeat dosing in 12 hours is required. There is no marketed version of this, but resourceful people who combine pills from an available pack that total 100 mcg of ethinyl estradiol will effectively reduce their risks of pregnancy. A listing of acceptable regimens based on commonly available combined oral contraceptive pills is available <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.bedsider.org%2Ffeatures%2F88-the-yuzpe-method-effective-emergency-contraception-dating-back-to-the-70s&amp;token=0S1UYpn%2FP0phpQyBKxjL9OygroOq2rcnMiw7V6xylno6DpYM800H8bcU7y%2FM4zm2X6lzoOxDYwkjGlWjdSUSMZlYmOm4IgtrCtI2z7hC91PafjMqmXzIuQxoBU2me0loSMoYl3TsUPl6ebG7p8SFwQ%3D%3D&amp;TOPIC_ID=5475" target="_blank">online</a>. While the Yuzpe method is less effective and produces more side effects than the other oral EC methods, its wide availability and low cost can be good reasons to use it. This may be of greater importance in rural areas with greater challenges to access and privacy.</p><p></p><p class="headingAnchor" id="H1632431985"><span class="h1">HOW EFFECTIVE IS EMERGENCY CONTRACEPTION AT PREVENTING PREGNANCY?</span></p><p class="headingAnchor" id="H3036760769"><span class="h2">Baseline risk of pregnancy</span><span class="headingEndMark"> — </span>Although pregnancy risk for EC users is very difficult to calculate, any person who presents for EC should be evaluated for it. The risk depends on many factors including whether the patient had sex in the fertile window, how many unprotected intercourse (UPI) exposures the patient had in the cycle, age, and imperfect use of a contraceptive method (condom slipped off or withdrawal) versus use of no method. Most EC users have not had UPI during the fertile window [<a href="#rid45">45,46</a>], and fewer than one-half of those presenting for EC have sperm present in the vagina [<a href="#rid47">47</a>]. However, EC users are still at high risk of pregnancy in the year after using oral EC, with annual pregnancy rates of 5 to 12 percent [<a href="#rid26">26,48-51</a>]. Thus, we discuss ongoing contraceptive needs with patients who present for EC. (See <a class="local">'Initiating ongoing contraception'</a> below.)</p><p class="headingAnchor" id="H3853587298"><span class="h2">Emergency contraception efficacy</span><span class="headingEndMark"> — </span>Intrauterine devices (IUDs) are the most effective EC method. The risk of pregnancy following placement of a copper 380 mm<sup>2</sup> IUD is 0.1 percent (ie, the copper 380 mm<sup>2</sup> IUD reduces the risk of pregnancy after UPI by more than 99 percent) [<a href="#rid20">20</a>]. Early data suggest the 52 mg <a class="drug drug_general" data-topicid="104542" href="/d/drug information/104542.html" rel="external">levonorgestrel</a> (LNG 52 mg) IUD has an unintended pregnancy rate of 0.3 percent [<a href="#rid21">21</a>]. This efficacy is not statistically less than the copper 380 mm<sup>2</sup> IUD and is five- to eightfold lower (ie, more effective) compared with oral medications.</p><p>Relative to the IUDs, efficacy drops considerably with use of oral EC methods. Data from trials comparing <a class="drug drug_general" data-topicid="15626" href="/d/drug information/15626.html" rel="external">ulipristal</a> acetate (UPA) and oral LNG report respective pregnancy rates of 1.8 percent for UPA versus 2.6 percent for LNG [<a href="#rid5">5,52-55</a>]. An earlier trial by the World Health Organization (WHO) that compared oral LNG with <a class="drug drug_general" data-topicid="10263" href="/d/drug information/10263.html" rel="external">mifepristone</a> 10 mg reported a pregnancy risk of 1.5 percent for both [<a href="#rid52">52</a>], though mifepristone efficacy likely varies with dose [<a href="#rid6">6</a>]. Importantly, the risk of pregnancy increases with increasing body mass index (BMI) for both UPA and LNG [<a href="#rid56">56</a>]. Other risk factors for pregnancy despite EC use include UPI in the fertile window and continued UPI after EC use [<a href="#rid56">56</a>]. (See <a class="local">'Initiation and use'</a> below and <a class="local">'Impact of body weight'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Device-specific efficacy data</strong> – Overall, the level of confidence in copper T380A IUD EC data, based on the large number of trials and participants reporting pregnancy rates ≤0.1 percent, is far greater than one efficacy study of the LNG 52 mg IUD EC. An ongoing prospective observational trial is attempting to reproduce the initial LNG 52 mg IUD EC results. This study will enroll 853 LNG 52 mg IUD EC users at eight diverse sites in the United States [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Copper 380 mm</strong><strong><sup>2</sup></strong><strong> IUD </strong>– Data supporting use of the copper 380 mm<sup>2</sup> IUD come from a systematic review of over 7000 IUD placements, including eight different IUD types (including a small proportion of inert IUDs) inserted over varying time frames in six countries between 1979 and 2011, that reported a pregnancy rate of 0.09 percent [<a href="#rid20">20</a>]. The largest study included used only the copper T380A IUD and reported zero pregnancies among 1963 users [<a href="#rid57">57</a>]. Review of included studies that limited the time of insertion to 120 hours (ie, five days) reported failure rates of 0 to 0.1 percent. Unlike oral methods of EC, there is no evidence to suggest that copper 380 mm<sup>2</sup> IUD efficacy for EC varies by menstrual cycle timing, time since UPI, the number of episodes of UPI in the cycle of EC use, or the patient's body weight. A growing pool of data supports IUD EC efficacy when inserted more than five days after UPI [<a href="#rid45">45,58</a>]<em>.</em> Another benefit of the copper 380 mm<sup>2</sup> IUD is provision of ongoing contraception in addition to EC; it is highly effective at preventing pregnancy for up to 12 years [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>LNG 52 mg IUD</strong> – Research on the LNG 52 mg IUD for EC is newer and less robust. In the case of the <a class="drug drug_general" data-topicid="93719" href="/d/drug information/93719.html" rel="external">copper IUD</a> for EC, our confidence in the low pregnancy rate (0.1 percent) comes from a multitude of studies conducted in a variety of countries with consistent agreement in results (excluding one study from Egypt). In comparison, data for the LNG 52 mg IUD for EC come from a single noninferiority trial in which 317 participants received the <a class="drug drug_general" data-topicid="104541" href="/d/drug information/104541.html" rel="external">LNG IUD</a> and reported one-month pregnancy outcomes [<a href="#rid21">21</a>]. That study randomly assigned 711 females who presented within five days of UPI and desired EC to either an LNG 52 mg or copper 380 mm<sup>2</sup> IUD. Participants reported pregnancy rates of 0.3 percent (1 of 317) and 0.0 percent (0 of 321), respectively [<a href="#rid21">21</a>]. All trial participants had a negative urine pregnancy test at the time of IUD placement and were masked to the IUD type they received for the first month of use. The pre-study noninferiority margin of 2.5 percentage points was met as the pregnancy incidence difference between the two methods was 0.3 percent (95% CI -0.9 to 1.8 percent). This study concluded the LNG 52 mg IUD is not less effective than (or noninferior to) the copper 380 mm<sup>2</sup> IUD for EC. These results do not permit us to say that one IUD is superior or inferior to the other for EC.</p><p></p><p class="bulletIndent2">Adverse events causing the participants to seek medical care within the first month after IUD placement were low in both groups (5.2 percent of LNG 52 mg IUD users and 4.9 percent of copper 380 mm<sup>2</sup> IUD users). The most common adverse events were bleeding, cramping, and pain. Study strengths were inclusion of patients with both a range of BMIs and more than one episode of UPI.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="15626" href="/d/drug information/15626.html" rel="external">Ulipristal</a><strong> acetate</strong> – Large prospective studies of UPA, the most effective oral EC method, report single-cycle pregnancy rates of 1.2 to 1.8 percent [<a href="#rid5">5,44,54</a>]. In clinical practice, the author informs UPA EC users that if 100 people use the medicine, one to two people will have a positive pregnancy test in the next two to three weeks. In these studies, UPA efficacy did not drop over the 120-hour (ie, five-day) time frame after UPI. A meta-analysis of two trials comparing UPA with LNG demonstrated that UPA was more likely to prevent pregnancy in the first 120 hours after UPI (odds ratio 0.55, 95% CI 0.32-0.93) [<a href="#rid54">54</a>]. In pharmacokinetic evaluations, UPA more effectively prevented ovulation at all times relative to LNG, and UPA continued to prevent ovulation through the onset of the luteinizing hormone (LH) surge, while LNG only prevented ovulation prior to the surge [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Oral LNG</strong> – For LNG, single-cycle pregnancy rates with a single episode of UPI range from 1.7 to 2.6 for all enrolled in large trials [<a href="#rid41">41,44,54</a>]. The highest risk of pregnancy for oral LNG EC users, 7.3 percent, is in patients reporting repeated acts of intercourse later in the cycle [<a href="#rid56">56</a>]. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Duration of efficacy</strong> – Although the LNG package insert states that efficacy is maintained up to 72 hours from UPI, subsequent studies have demonstrated no reduction in efficacy for up to 120 hours (ie, five days) from UPI [<a href="#rid40">40,59,60</a>]. The 72-hour window was based on data from earlier trials [<a href="#rid52">52,61</a>]. While the author counsels patients that LNG can be used up to five days from UPI, patients are also advised to take LNG as soon as possible to increase the likelihood that the medication is used prior to the LH surge. After the LH surge, LNG is no longer effective. (See <a class="local">'Mechanisms of action'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Combined treatment with </strong><a class="drug drug_general" data-topicid="9781" href="/d/drug information/9781.html" rel="external">piroxicam</a> – Taking oral LNG with a single dose of piroxicam appears to increase efficacy (ie, lower the unintended pregnancy rate). A trial including 860 patients with a single act of UPI reported that patients receiving combined treatment with LNG and piroxicam 40 mg orally had lower pregnancy rates compared with those receiving LNG/placebo (0.2 versus 1.7 percent, OR 0.20, 95% CI 0.02-0.91) [<a href="#rid41">41</a>]. Although definitive conclusions cannot be made from one trial that included a patient population with only a single UPI exposure, dual treatment is reasonable if piroxicam is readily available (ie, over the counter) and there are no contraindications to its use [<a href="#rid41">41</a>]. Of note, this study was conducted in Hong Kong with participants with a mean BMI of 21 kg/m<sup>2</sup> (only 10 percent of whom had a weight &gt;70 kg or BMI &gt;26 kg/m<sup>2</sup>). This creates some limitations in applying the data to heavier populations.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10263" href="/d/drug information/10263.html" rel="external">Mifepristone</a> – The aggregate of data supporting mifepristone use shows that it is more effective than the Yuzpe method and likely more effective than LNG at the low-dose range (&lt;25 mg) and the mid-dose range (25 to 50 mg) [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Data limitations</strong> – One important consideration when using published data to evaluate pregnancy risk among EC users in the clinical setting is that nearly all of these studies limit inclusion criteria to females having only a single episode of UPI in the cycle with EC treatment [<a href="#rid44">44</a>]. However, among routine EC users, multiple episodes of UPI occur in the cycle that EC is used. In a study of 176 IUD EC users who were known to not be pregnant, 43 percent reported multiple episodes of UPI in the 14 days prior to presenting for EC [<a href="#rid62">62</a>]. Those with multiple episodes of UPI in the cycle are the EC users with the highest risk of pregnancy. The IUDs provide additional benefit for this group as they are the most effective EC method and provide ongoing pregnancy prevention for this group that is likely at continued high risk.</p><p></p><p class="headingAnchor" id="H2948724098"><span class="h1">WHICH METHOD SHOULD I PICK?</span></p><p class="headingAnchor" id="H4282350479"><span class="h2">Comparison of all methods</span><span class="headingEndMark"> — </span>Selection of an EC agent is driven by patient preference but must also consider method characteristics, availability, and cost  (<a class="graphic graphic_table graphicRef120627" href="/d/graphic/120627.html" rel="external">table 1</a>). Patient-important variables include desire to initiate the most effective EC, desire for long-term contraception, and desire to initiate hormonal non-IUD contraception  (<a class="graphic graphic_algorithm graphicRef130902" href="/d/graphic/130902.html" rel="external">algorithm 1</a>). While intrauterine devices (IUDs) are the most effective EC method, they require a visit with a medical provider, take the most time to obtain, and are the most expensive for those without insurance coverage. In addition, some people simply do not want an IUD because they have previously tried one without satisfaction, do not desire a foreign material in their body, or have a range of other reasons. <a class="drug drug_general" data-topicid="15626" href="/d/drug information/15626.html" rel="external">Ulipristal</a> acetate (UPA) is the most effective oral method but requires a prescription and is not stocked by all pharmacies. Finally, oral <a class="drug drug_general" data-topicid="104542" href="/d/drug information/104542.html" rel="external">levonorgestrel</a> (LNG), the least effective oral agent, should be available in any pharmacy without a prescription and should be the easiest to obtain. However, this generally requires an out-of-pocket expense in excess of USD $40 (can be as low as USD $10 with internet-based purchasing), and it is not provided in all pharmacies or may be placed behind the pharmacy counter in others. The choice of EC must ultimately balance all of these factors.</p><p class="headingAnchor" id="H1259026792"><span class="h2">Advantages of intrauterine devices for emergency contraception</span><span class="headingEndMark"> — </span>IUDs have significant advantages over oral EC methods, and there are very few contraindications to IUD EC use. Main advantages of IUDs for EC include:</p><p class="bulletIndent1"><span class="glyph">●</span>Both are highly effective and more effective than oral EC methods. As the efficacy data for the LNG 52 mg (0.3 percent) are limited compared with the copper 380 mm<sup>2</sup> IUD (0.1 percent), the body of evidence does not permit us to say that one IUD is superior or inferior to the other for EC. However, the data supporting <a class="drug drug_general" data-topicid="93719" href="/d/drug information/93719.html" rel="external">copper IUD</a> EC efficacy are certainly more robust than that for the LNG 52 mg IUD.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Continue to provide ongoing, highly effective contraception for years after EC use. One-year continuation rates of approximately 60 percent have been reported for both devices [<a href="#rid29">29</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Can be used in individuals of any weight or body mass index (BMI) without a decrease in EC efficacy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Work well for individuals regardless of timing of the menstrual cycle relative to unprotected intercourse (UPI).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Data suggest they are effective for UPI occurring 6 to 14 days prior to IUD insertion [<a href="#rid63">63</a>].</p><p></p><p class="headingAnchor" id="H3828068023"><span class="h2">Intrauterine device selection</span><span class="headingEndMark"> — </span>IUD selection for EC is guided by user preferences for the unique characteristics of each device. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Favoring the</strong> <strong>copper 380 mm</strong><strong><sup>2</sup></strong><strong> IUD </strong>– The copper 380 mm<sup>2</sup> IUD provides the most effective EC method, can remain in place up to 12 years [<a href="#rid27">27,64</a>], maintains regular menstrual cycles, and does not contain hormones. (See  <a class="medical medical_review" href="/d/html/116579.html" rel="external">"Intrauterine contraception: Background and device types", section on 'Copper IUD'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Favoring the LNG 52 mg IUD</strong> – The LNG 52 mg IUD results in less or no menstrual bleeding and cramping, can remain in place up to eight years [<a href="#rid65">65</a>], and has the potential for amenorrhea. An ongoing study will provide more precise efficacy data on the LNG 52 mg IUD for EC [<a href="#rid28">28</a>]. (See  <a class="medical medical_review" href="/d/html/116579.html" rel="external">"Intrauterine contraception: Background and device types", section on 'Levonorgestrel IUD'</a>.)</p><p></p><p>Past studies have reported only a minority of EC users (approximately one in eight) would consider an IUD [<a href="#rid66">66,67</a>]. It is not known how the option of the LNG 52 mg will impact the frequency of IUD use for EC.</p><p class="headingAnchor" id="H3190467232"><span class="h1">COUNSELING POINTS</span></p><p class="headingAnchor" id="H271984976"><span class="h2">Candidates</span><span class="headingEndMark"> — </span>Any reproductive female, of any age, who has had unprotected or under-protected vaginal intercourse and wishes to reduce the risk of pregnancy is a potential EC candidate [<a href="#rid68">68,69</a>]. The author and other experts advise that every individual who thinks they may be at risk of unwanted pregnancy and considers taking EC should take it. This advice is based on study data indicating that asking women to identify their fertile window based on menstrual cycle dates is highly inaccurate when compared with laboratory testing [<a href="#rid46">46</a>].</p><p>EC is safe for the majority of patients. Pregnancy is the only absolute contraindication to EC use because EC will not work if a pregnancy is established [<a href="#rid37">37,39</a>]. Individuals with a contraindication to the copper 380 mm<sup>2</sup> IUD (eg, current pelvic inflammatory disease or a uterine anomaly) or oral medications (ie, drug allergy) should receive alternate methods. The US Medical Eligibility Criteria for Contraceptive Use suggests no restrictions for UPA or LNG EC for breastfeeding individuals [<a href="#rid22">22</a>]. (See <a class="local">'Special populations'</a> below.)</p><p class="headingAnchor" id="H3560875706"><span class="h2">Impact of body weight</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tcu380A IUD</strong> <strong>and LNG 52 mg IUD </strong>– Body weight does not impact the efficacy of either IUD, which in part contributes to its overall high efficacy [<a href="#rid20">20,21</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral medications</strong> – EC efficacy for LNG appears to decrease with increasing body mass index (BMI), both for overweight (BMI 25 to 29.9 kg/m<sup>2</sup>) and obese (BMI ≥30 kg/m<sup>2</sup>) individuals. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Oral </strong><a class="drug drug_general" data-topicid="104542" href="/d/drug information/104542.html" rel="external">levonorgestrel</a> – Studies suggest that LNG EC may not reduce the risk of pregnancy for individuals with obesity [<a href="#rid56">56,70</a>]. However, LNG data from pooled World Health Organization (WHO) studies reported a less dramatic effect [<a href="#rid71">71</a>]. This information has public health significance, as the prevalence of obesity among United States females ages 20 to 34 exceeds one-third of the population (34.8 percent) [<a href="#rid72">72</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Pharmacokinetic data</strong> – Pharmacokinetic data provide insight into the clinical data. A study that compared serum metrics following the 1.5 mg oral dose of LNG in 10 normal-weight (mean BMI 22 kg/m<sup>2</sup>), 11 obese (mean BMI 34.4 kg/m<sup>2</sup>), and 5 extremely obese (mean BMI 46.6 kg/m<sup>2</sup>) women reported lower mean total serum maximum concentrations and areas under the curve for obese and extremely obese women [<a href="#rid73">73</a>]. A study comparing serum LNG levels in five women with normal BMI (18 to 24.9 kg/m<sup>2</sup>) versus five obese women (BMI ≥30 kg/m<sup>2</sup>) reported that, after an oral dose of 1.5 mg LNG, obese women had LNG serum levels one-half those of the controls [<a href="#rid74">74</a>]. When the oral LNG dose was doubled to 3 mg, the serum level in obese women reached the level of the 1.5 mg control women. A different study that compared serum levels of LNG and UPA in 16 normal and obese women, in a crossover design, reported that obese participants had LNG levels one-half of the normal BMI participants [<a href="#rid75">75</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Role of doubled dose</strong> – One proposed solution has been to use double the usual LNG dose (3 mg instead of 1.5 mg) for individuals with obesity. One study reported similar serum LNG levels for five self-reported women with obesity compared with five control women when those with obesity received double the LNG dose (3.0 mg versus 1.5 mg) [<a href="#rid74">74</a>]. However, in a subsequent study that assessed timing of ovulation in 70 self-reported women with obesity who received LNG 1.5 mg or 3 mg, ovulation (identified by follicle rupture) occurred for similar numbers of participants in the two groups (LNG 1.5 mg: 18 in 35 [51 percent] and LNG 3.0 mg: 24 in 35 [69 percent], p = 0.14) [<a href="#rid76">76</a>]. In addition, for those with evidence of follicle rupture, timing of ovulation was similar for both groups (ie, there was no delay). Thus, we do not use a doubled dose of LNG for EC in individuals with obesity as it does not appear to suppress or delay ovulation adequately to function as EC for these patients.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="15626" href="/d/drug information/15626.html" rel="external">Ulipristal</a><strong> acetate</strong> – The impact of overweight and obesity on UPA levels is unclear as evidence is limited. In a cross-over study comparing serum levels of LNG and UPA in 32 self-reported women of normal weight or with obesity, serum UPA levels did not differ between the groups [<a href="#rid75">75</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Impact of malabsorptive bariatric surgery</strong> – For those who have had malabsorptive bariatric procedures, LNG absorption is likely compromised, and LNG levels are low [<a href="#rid77">77</a>]. Data for UPA are not available for these patients. Thus, the most effective, and possibly the only effective, EC method in this group are the IUDs. (See  <a class="medical medical_review" href="/d/html/88536.html" rel="external">"Bariatric procedures for the management of severe obesity: Descriptions", section on 'Procedures endorsed by the ASMBS'</a>.)</p><p></p><p class="headingAnchor" id="H2157722723"><span class="h2">Side effects</span><span class="headingEndMark"> — </span>Overall, all EC methods are safe and well tolerated; the side effect profiles vary by the method.</p><p>For the copper 380 mm<sup>2</sup> and LNG 52 mg IUD, side effects can include abdominal or pelvic pain resulting from insertion, bleeding, uterine perforation, and, rarely, infection. These issues, which are generally of low risk and treatable, are discussed in detail in a related topic. (See  <a class="medical medical_review" href="/d/html/5422.html" rel="external">"Intrauterine contraception: Management of side effects and complications"</a>.)</p><p>Both UPA and oral LNG are exceptionally safe and avoid the rare major complications of combined hormonal contraception, specifically estrogen-related thrombogenic events. In the initial clinical trials, common side effects of UPA included headache (18 percent), abdominal pain (12 percent), nausea (12 percent), dysmenorrhea (9 percent), fatigue (6 percent), and dizziness (5 percent) [<a href="#rid37">37</a>]. For LNG, common side effects were similar and included menstrual changes, nausea, lower abdominal pain, fatigue, headache, dizziness, breast pain, and vomiting [<a href="#rid39">39</a>].</p><p>For the Yuzpe method of using combined estrogen and LNG birth control pills, the main side effects are nausea and vomiting, which occur more often with this method compared with UPA, LNG, or <a class="drug drug_general" data-topicid="10263" href="/d/drug information/10263.html" rel="external">mifepristone</a> [<a href="#rid44">44,68</a>]. For this reason, patients using this method are often prescribed anti-nausea medication as well. (See <a class="local">'Initiation and use'</a> below.)</p><p class="headingAnchor" id="H3561416219"><span class="h2">Sexually transmitted infection risk</span><span class="headingEndMark"> — </span>Use of EC does not reduce the risk of sexually transmitted infections (STIs). We discuss regular condom use with all patients who are at risk of acquiring an STI. Information on STI screening is presented separately. (See  <a class="medical medical_review" href="/d/html/7596.html" rel="external">"Screening for sexually transmitted infections"</a>.)</p><p class="headingAnchor" id="H766816012"><span class="h2">Patient satisfaction</span><span class="headingEndMark"> — </span>Data on patient satisfaction with various EC methods are sparse. A prospective study of 79 women choosing either the copper 380 mm<sup>2</sup> IUD or UPA for EC reported that, at six-month follow-up, 86 percent of copper 380 mm<sup>2</sup> IUD users said they would recommend the copper 380 mm<sup>2</sup> IUD for EC and 64 percent had already recommended the method [<a href="#rid78">78</a>].</p><p class="headingAnchor" id="H2198118363"><span class="h1">ADMINISTRATION</span></p><p class="headingAnchor" id="H2451426975"><span class="h2">Common clinical scenarios</span><span class="headingEndMark"> — </span>Most EC users use oral EC and obtain it without an office visit with a medical provider. However, there are several clinical encounters where it is appropriate to discuss EC alternatives and characteristics. Clinicians should be aware that patients who could benefit from EC do not always know that it is available or how to access it.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Identified unprotected intercourse (UPI)</strong> – In some cases, patients inform the clinician that they had UPI in the last five days. However, from the author's clinical experience in a variety of primary care, female reproductive health, and family planning settings, few clients schedule an appointment specifically to request EC. More commonly, recent UPI is disclosed as part of the sexual history for another related issue. Thus, clinicians can consider every visit with a reproductive-age female an opportunity to ask about EC need or provide information about potential future use, if needed, along with a prescription for <a class="drug drug_general" data-topicid="15626" href="/d/drug information/15626.html" rel="external">ulipristal</a> acetate (UPA).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>New contraceptive start</strong> – A patient who presents to start or change contraceptive methods may report recent UPI upon questioning, and thus the opportunity for EC use becomes apparent. The Centers for Disease Control and Prevention (CDC) provides questions to reasonably exclude pregnancy  (<a class="graphic graphic_table graphicRef67567" href="/d/graphic/67567.html" rel="external">table 2</a>). If the patient answers "yes" to any of these six questions at the time of the visit, then contraception can be started directly, without using EC, and no urine pregnancy test is needed. However, people commonly present for care when they are not in the first seven days of their menstrual cycle and have had intercourse since the start of their last normal menses, which eliminates two of the CDC questions. In these situations, the choice of EC depends in part on the desired contraceptive and the balance of maximum EC efficacy versus immediate contraceptive start. (See <a class="local">'Which method should I pick?'</a> above and <a class="local">'Initiating ongoing contraception'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sexual assault</strong> – In cases where individuals present for care related to recent sexual assault or it is revealed during a clinical encounter, EC should be offered [<a href="#rid79">79</a>]. The Royal College of Obstetricians and Gynaecologists Faculty of Sexual and Reproductive Healthcare recommends offering the copper 380 mm<sup>2</sup> intrauterine device (IUD), the most effective method of EC, to everyone at risk of pregnancy after a sexual assault [<a href="#rid80">80</a>]. Ideally, this should immediately follow forensic examination for specimen collection. Emergency departments in other regions, including the United States, are often not equipped for IUD insertion as part of sexual assault evaluation. (See  <a class="medical medical_review" href="/d/html/2765.html" rel="external">"Evaluation and management of adult and adolescent sexual assault victims in the emergency department"</a>.)</p><p></p><p class="bulletIndent1">If the copper 380 mm<sup>2</sup> IUD is not available or desired by the patient, the patient should be offered oral EC. Many emergency departments now have an established protocol for providing EC in this setting, though by law only 18 states and the District of Columbia require offering EC to sexual assault victims [<a href="#rid81">81</a>].</p><p></p><p class="headingAnchor" id="H3010472608"><span class="h2">Initiation and use</span><span class="headingEndMark"> — </span>The use of oral EC does <strong>not</strong> require a routine physical examination, pregnancy test, or laboratory tests [<a href="#rid68">68,80</a>]. Unless patients have missed a menstrual cycle or think they may be pregnant  (<a class="graphic graphic_table graphicRef67567" href="/d/graphic/67567.html" rel="external">table 2</a>), use of EC should not be delayed or withheld to check for pregnancy [<a href="#rid82">82</a>]. By contrast, it is clinically appropriate to conduct a urine pregnancy test prior to IUD EC placement as this has been the practice for studies of IUDs for EC.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Copper 380 mm</strong><strong><sup>2</sup></strong><strong> and </strong><a class="drug drug_general" data-topicid="104542" href="/d/drug information/104542.html" rel="external">levonorgestrel</a> <strong>(LNG) 52 mg IUDs</strong> – IUDs should only be inserted by clinicians who have received appropriate training. Detailed instructions for IUD insertion are reviewed separately. (See  <a class="medical medical_review" href="/d/html/3267.html" rel="external">"Intrauterine contraception: Insertion and removal"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Standard insertion timing</strong> – The copper 380 mm<sup>2</sup> and LNG 52 mg IUDs can be inserted up to five days from UPI and likely longer [<a href="#rid23">23,24,63,82</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Extended timing of insertion</strong> – There is a growing body of data that demonstrates low pregnancy rates with UPI occurring beyond five days prior to IUD placement.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In a secondary analysis of a trial comparing copper 380 mm<sup>2</sup> and LNG 52 mg IUDs in 655 participants presenting for EC, similar pregnancy rates were reported by individuals with all UPI five or fewer days prior to IUD insertion compared with those also reporting UPI 6 to 14 days prior to IUD insertion (0.2 percent, 95% CI -0.2 to 0.5) [<a href="#rid63">63</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For the Tcu380A IUD, an aggregated data set reported no pregnancies in 134 people receiving an IUD and having UPI 6 to 14 days prior to IUD placement (0 percent, 97.5% CI 0-2.7 percent) [<a href="#rid83">83</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Two other studies reported zero pregnancies among an additional 116 participants reporting UPI more than five days prior to copper 380 mm<sup>2</sup> IUD placement. Collectively, the three Tcu380A studies would provide a pregnancy risk of 0 percent (97.5% CI 0-1.5 percent) [<a href="#rid45">45,58,83</a>]. This same dataset reported one pregnancy among 187 LNG 52 mg IUD users with UPI 6 to 14 days prior to IUD placement (0.5 percent, 95% CI 0.01-2.9 percent) [<a href="#rid84">84</a>].</p><p></p><p class="bulletIndent2">Even prior to the publication of most of these data, the Society of Obstetricians and Gynaecologists of Canada advised IUD use within seven days of UPI, and the World Health Organization says the copper 380 mm<sup>2</sup> IUD can be inserted beyond five days from UPI if the timing of ovulation can be estimated and the insertion does not occur more than five days after ovulation [<a href="#rid23">23,24</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Our approach</strong> – Based on the information above and other studies, we take the following approach for anyone who wants an IUD, reports UPI &gt;5 days prior, and has a negative urine pregnancy test:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Counsel about risk of pregnancy</strong> – We counsel that the risk of pregnancy for this menstrual cycle with IUD placement is very low (likely &lt;1 percent). This estimate is extrapolated from a much smaller data set compared with data supporting other EC recommendations because identifying people &gt;5 days from UPI is more challenging and these individuals were excluded from most EC studies. It is difficult to obtain information on pregnancy risk with UPI &gt;5 days prior without IUD placement to compare.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>IUD insertion &gt;5 days after UPI </strong>– For individuals who desire an IUD insertion (either copper 380 mm<sup>2</sup> or LNG 52 mg IUD) for EC and report UPI &gt;5 days prior, we counsel patients that they must have a negative pregnancy test, accept the potential risk of conception with an IUD in place, understand the follow-up care plan, and be able to return should they have a positive pregnancy test two to four weeks after IUD insertion. Our willingness to insert an IUD for EC beyond the usual time frame is extrapolated from studies reporting that individuals who are required to have a delayed contraceptive start are more likely to experience unintended pregnancy compared with individuals who receive immediate contraception [<a href="#rid85">85-89</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral EC</strong> – Oral EC should be taken as soon as possible after UPI. The maximum allowable interval varies by medication.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>UPA</strong> – UPA is given as a single 30 mg oral dose to be taken as soon as possible after UPI, up to a five-day (120-hour) interval [<a href="#rid37">37</a>]. In our practice, we include refills on the prescription for future use. If UPI occurred four or five days prior to the visit, we inform patients desiring oral EC of the superior efficacy of UPA over LNG in this setting. The patient is advised to use a barrier method (condoms) or abstain from vaginal intercourse for at least five days after taking UPA. Hormonal contraception should not be started sooner than five days after taking UPA because exposure to progestins from seven days prior to five days after UPA use can decrease UPA's ability to block ovulation [<a href="#rid90">90</a>]. The section on initiating ongoing contraception addresses this in greater detail. (See <a class="local">'Initiating ongoing contraception'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>LNG</strong> – LNG is available as a single oral 1.5 mg dose, to be taken as soon as possible after UPI, up to three days (72 hours) [<a href="#rid39">39</a>]. There may be some efficacy up to five days (120 hours) [<a href="#rid39">39,40,54</a>]. LNG efficacy is likely higher the earlier the drug is taken within the 72-hour window. The longer someone who has not yet ovulated waits to take LNG EC, the greater the chance they may progress to the point of the luteinizing hormone (LH) surge and thus lessen the efficacy of LNG EC. In the United States, single-dose LNG (available under multiple commercial names, including Plan B One-Step) is available over the counter without age restrictions [<a href="#rid68">68</a>]. Although LNG has also been available in two doses of 0.75 mg each, the one-dose approach is favored because of simpler dosing and efficacy that is at least as good [<a href="#rid52">52,91</a>]. Combined treatment with <a class="drug drug_general" data-topicid="9781" href="/d/drug information/9781.html" rel="external">piroxicam</a> 40 mg orally, taken at the same time, may increase LNG efficacy [<a href="#rid41">41</a>]. (See <a class="local">'Emergency contraception efficacy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10263" href="/d/drug information/10263.html" rel="external">Mifepristone</a> – Outside of the United States, mifepristone is available for EC in oral doses of 10 to 25 mg. Dose selection depends on regional availability.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Yuzpe method of combined oral contraceptive pills</strong> – Combined oral contraceptive pills that contain ethinyl estradiol and either <a class="drug drug_general" data-topicid="141983" href="/d/drug information/141983.html" rel="external">norgestrel</a> or LNG can be used as EC but must be taken in a dosing pattern that is very different from use as an oral contraceptive. Data are lacking on use of oral contraceptive pills with other progestins for EC. To provide EC, the initial dose must contain the equivalent of 100 to 120 mcg of ethinyl estradiol and 0.5 to 0.6 mg of LNG (or the equivalent) [<a href="#rid6">6</a>]. The same dose is then repeated 12 hours after the first dose. A list of contraceptive pill brands and how to use them for EC is presented <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.bedsider.org%2Ffeatures%2F88-the-yuzpe-method-effective-emergency-contraception-dating-back-to-the-70s&amp;token=0S1UYpn%2FP0phpQyBKxjL9OygroOq2rcnMiw7V6xylno6DpYM800H8bcU7y%2FM4zm2X6lzoOxDYwkjGlWjdSUSMZlYmOm4IgtrCtI2z7hC91PafjMqmXzIuQxoBU2me0loSMoYl3TsUPl6ebG7p8SFwQ%3D%3D&amp;TOPIC_ID=5475" target="_blank">online</a>. Some clinicians also advise taking <a class="drug drug_general" data-topicid="9597" href="/d/drug information/9597.html" rel="external">meclizine</a> 50 mg orally with the first dose to reduce nausea. Use of the Yuzpe method should be reserved for situations where people can obtain combined oral contraceptive pills but cannot obtain a dedicated EC product within two to three days.</p><p></p><p class="headingAnchor" id="H1939877234"><span class="h2">What if oral medication is vomited?</span><span class="headingEndMark"> — </span>Data to guide repeat dosing of oral EC in the setting of vomiting are lacking, in part because vomiting is rare with LNG and UPA formulations [<a href="#rid6">6</a>]. At least one guideline advises repeat dosing of oral EC if the patient vomits the medication within three hours of ingestion [<a href="#rid92">92</a>]. When receiving clinical calls from patients on this topic, the author anticipates that if the medication level was high enough to induce vomiting, then it was also likely high enough to interrupt ovulation. However, for patients with a secondary reason for vomiting (eg, viral illness) or a short time interval from initial ingestion to vomiting (&lt;1 hour), the author asks the patient to take a repeat dose.</p><p class="headingAnchor" id="H63925017"><span class="h2">What happens to the menstrual cycle?</span><span class="headingEndMark"> — </span>For patients using oral EC, the menstrual period typically restarts within one week of the anticipated date [<a href="#rid60">60</a>]. Resumption of menses within a week of the anticipated start is more common following UPA than LNG; menstrual delay is most common following <a class="drug drug_general" data-topicid="10263" href="/d/drug information/10263.html" rel="external">mifepristone</a> and appears to be dose related [<a href="#rid44">44</a>]. Irregular bleeding or spotting can also occur and continue up to a month after treatment [<a href="#rid68">68</a>]. Any irregular bleeding should resolve without treatment. We reevaluate patients with persistent bleeding to exclude pregnancy. </p><p>Use of the copper 380 mm<sup>2</sup> IUD as EC does not significantly impact the timing of the menstrual cycle. Data evaluating the return of the menstrual cycle after LNG 52 mg IUD placement for EC are not yet available, though it is reasonable to expect an increase in bleeding and spotting in the first three months of <a class="drug drug_general" data-topicid="104541" href="/d/drug information/104541.html" rel="external">LNG IUD</a> use as is typical when placed for ongoing contraception. (See  <a class="medical medical_review" href="/d/html/116579.html" rel="external">"Intrauterine contraception: Background and device types", section on 'Impact of device type on bleeding pattern'</a>.)</p><p class="headingAnchor" id="H2135981311"><span class="h2">Can oral emergency contraception be used again in the same cycle?</span><span class="headingEndMark"> — </span>Both UPA and LNG can be used multiple times in the same menstrual cycle, although initiation of a proven contraceptive method is preferred to this approach [<a href="#rid68">68</a>]. Oral LNG 1.5 mg has been tested as an as-needed contraceptive for women with &lt;6 episodes of intercourse per month [<a href="#rid93">93</a>]. Among 321 enrollees, there were 142 women-years of use. The typical-use pregnancy rate was 7.1 per 100 women-years. More than 80 percent of users had frequent bleeding episodes, defined as more than five per 90-day period, and despite this, 90 percent of participants said they would use the method again.</p><p class="headingAnchor" id="H484054028"><span class="h2">Should I prescribe emergency contraception in advance?</span><span class="headingEndMark"> — </span>Providing a prescription for UPA in advance for anyone interested is reasonable, along with information about the need to delay starting hormonal contraception for five days after UPA use. In addition, information about over-the-counter availability of oral LNG for EC is appropriate. The International Consortium for Emergency Contraception advises providing an advanced prescription or supply of EC because no clinician screening or assessment is required and this enables treatment to be started as soon as possible [<a href="#rid94">94</a>]. One approach to this is to offer a prescription for UPA and information about oral LNG EC available over the counter for any person starting a new contraceptive method. For those who decline advance provision, practices can inform clients that they will prescribe by telephone without an office visit in the future, if needed. While advance provision usually means providing education and treatment options for females, it is entirely reasonable to provide the same for males who are heterosexually active [<a href="#rid95">95</a>].</p><p>While advance provision of EC is both logical and reasonable, a meta-analysis of 11 trials did not show a decrease in overall pregnancy rates over 12 months with this approach (odds ratio 0.98, 95% CI 0.76-1.25) [<a href="#rid96">96</a>]. Advance provision did result in increased EC use (both single and multiple use) as well as use sooner after UPI. Rates of sexually transmitted infections (STIs), frequency of UPI, and changes in contraception did not increase with advance provision of EC.</p><p class="headingAnchor" id="H4120318596"><span class="h1">INITIATING ONGOING CONTRACEPTION</span></p><p class="headingAnchor" id="H2406251657"><span class="h2">Assess need for continued contraception</span><span class="headingEndMark"> — </span>EC use provides an opportunity to inquire about ongoing contraceptive needs  (<a class="graphic graphic_algorithm graphicRef130902" href="/d/graphic/130902.html" rel="external">algorithm 1</a>), but the author's experience suggests that there is a significant proportion of EC users who only want an EC method delivered with the fewest obstacles and are not interested in counseling on ongoing contraceptive methods. EC users should be offered ongoing contraception and may need a restart of a method they were previously on or a method they used intermittently. Sometimes, these patterns of inconsistent use are driven by challenges accessing a method or a desire to switch methods. These factors can be important drivers in selecting ongoing contraception. Individuals who do not wish to discuss ongoing contraceptive needs at the time of an EC visit may benefit from scheduling a future appointment to further discuss these issues.</p><p class="headingAnchor" id="H271905053"><span class="h2">When to start contraception after emergency contraception</span><span class="headingEndMark"> — </span>The future risk of pregnancy in those presenting for EC highlights the need for initiating ongoing contraception for those with interest. The timing of contraceptive start and need for backup contraception or abstinence vary with the EC method  (<a class="graphic graphic_table graphicRef121199" href="/d/graphic/121199.html" rel="external">table 3</a> and <a class="graphic graphic_algorithm graphicRef130902" href="/d/graphic/130902.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tcu380A copper 380 mm</strong><strong><sup>2 </sup></strong><strong>or </strong><a class="drug drug_general" data-topicid="104542" href="/d/drug information/104542.html" rel="external">levonorgestrel</a><strong> (LNG) 52 mg intrauterine devices (IUDs)</strong> – Both the copper 380 mm<sup>2</sup> and LNG 52 mg IUDs provide EC and ongoing contraception, with no need for an interval of backup contraception or abstinence. This is the simplest approach and provides the highest efficacy for both EC and contraception, particularly given that backup contraception is unlikely to be used. One study of 518 individuals given either the Tcu308A or LNG 52 IUDs reported that 64 percent resumed penile-vaginal intercourse within seven days of IUD insertion but only 16 percent used a form of back-up contraception [<a href="#rid97">97</a>]. No pregnancies occurred in either group. (See <a class="local">'Emergency contraception efficacy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="15626" href="/d/drug information/15626.html" rel="external">Ulipristal</a><strong> acetate (UPA) </strong>– Barrier and pericoital contraceptives (ie, nonhormonal contraception) can be used immediately after UPA treatment; no period of abstinence is required [<a href="#rid82">82</a>]. Women who desire progestin-containing contraceptives are advised to delay start of the contraceptive for at least five days from UPA ingestion [<a href="#rid82">82</a>]. There is concern that earlier start of a progestin-containing contraceptive could interfere with UPA function and reduce UPA's ability to block ovulation [<a href="#rid37">37,38,90</a>]. </p><p></p><p class="bulletIndent1">However, clinicians should be aware that the five-day delay is a conservative approach. Five days is also the duration of sperm viability after intercourse. As a result, an alternative approach is to begin hormonal contraception five days after the most recent episode of unprotected intercourse (UPI) [<a href="#rid98">98</a>]. A thoughtful commentary addressing this issue advised waiting five days from UPI (not UPA ingestion) and also cautioned about applying results from a study with desogestrel to other progestins and combined hormonal contraceptives [<a href="#rid98">98</a>]. In addition, the study author acknowledged that clinicians should counsel EC users to weigh risks of pregnancy from recent UPI against future pregnancy risk based on contraceptive access and ability to return for future care. An approach to dealing with these issues is presented in the reference [<a href="#rid99">99</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral LNG</strong> – Barrier and pericoital contraceptives (ie, nonhormonal contraceptives) can be used immediately after LNG treatment; no period of abstinence is required [<a href="#rid82">82</a>]. For anyone who selects LNG EC and desires a contraceptive method with a progestin, the advice is the same: provide oral LNG for EC, initiate the contraceptive method at the same time as the LNG EC, and either abstain from sex or use a backup method of contraception for one week [<a href="#rid82">82</a>]. Backup contraception can include condoms (female or male) or pericoital contraception (diaphragm, contraceptive sponge, or cervical cap).</p><p></p><p class="bulletIndent1">While this approach is the next simplest after copper 380 mm<sup>2</sup> IUD insertion, it is not the most effective EC option. However, this approach may be preferred when the risk of pregnancy from the recent episode of UPI is low and the user is more concerned about preventing future pregnancy. An advantage is that the desired contraceptive can be started immediately with a backup method for one week as indicated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10263" href="/d/drug information/10263.html" rel="external">Mifepristone</a> – Like LNG, mifepristone EC users can initiate any form of contraception with or immediately after EC. The patient should also use a backup barrier contraceptive or abstinence for the first week following mifepristone EC use.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Yuzpe method of combined estrogen-progestin oral contraceptives</strong> – Individuals who use the Yuzpe method can start any method of contraception after taking the second dose of EC pills [<a href="#rid82">82</a>]. Those who elect to start hormonal contraception are advised to abstain from vaginal intercourse or to use a backup contraceptive for seven additional days. Backup contraception can include condoms (female or male), diaphragm, contraceptive sponge, or cervical cap.</p><p></p><p class="headingAnchor" id="H1455357861"><span class="h2">Case scenarios by contraceptive type</span><span class="headingEndMark"> — </span>For females who present for EC and have a preferred contraceptive method to restart or initiate, the selection of EC is influenced by the planned contraceptive. The choice of EC agent must balance the potential impact of EC on the desired contraceptive method start time and the impact of the contraceptive itself on EC efficacy. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Individuals who desire an IUD for contraception (copper 380 mm</strong><strong><sup>2</sup></strong><strong> or LNG)</strong> – Patients who present for EC and wish to use an IUD for contraception can choose from the copper 380 mm<sup>2</sup> or LNG 52 mg IUD. However, if patients desire the absolute greatest level of certainty against pregnancy, greater consideration should be given to the <a class="drug drug_general" data-topicid="93719" href="/d/drug information/93719.html" rel="external">copper IUD</a>. (See <a class="local">'Initiation and use'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Individuals who desire a progestin-containing contraceptive</strong> – Progestin-containing contraceptives include the <a class="drug drug_general" data-topicid="104541" href="/d/drug information/104541.html" rel="external">LNG IUDS</a>; <a class="drug drug_general" data-topicid="8870" href="/d/drug information/8870.html" rel="external">etonogestrel implant</a>; depot <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">medroxyprogesterone acetate</a> (DMPA) injection; combined estrogen-progestin pills, patches, and rings; and progestin-only pills. For individuals who desire any of these methods other than the LNG IUD, the patient and clinician must balance oral EC efficacy with timing of initiation and efficacy of the desired progestin-containing contraceptive. While UPA is associated with lower pregnancy rates, it also requires a delayed start of progestin-containing contraceptives  (<a class="graphic graphic_table graphicRef121199" href="/d/graphic/121199.html" rel="external">table 3</a> and <a class="graphic graphic_algorithm graphicRef130902" href="/d/graphic/130902.html" rel="external">algorithm 1</a>), which may necessitate another visit (for the etonogestrel implant or DMPA injection) and may increase the patient's risk of future pregnancy if no contraception is started. However, as UPA is the most effective oral EC, it may be ideal for those at high risk of pregnancy based on recent UPI who prioritize reducing immediate pregnancy risk over ongoing contraception start. Oral LNG EC has a lower efficacy but can be given simultaneously with any progestin-containing contraceptive (plus seven days of abstinence or backup contraception). This approach may be preferred for individuals at lower risk of pregnancy relative to UPI and who prioritize immediate contraceptive start and/or avoiding repeat visits (and additional cost).</p><p></p><p class="bulletIndent1">For example, a person on cycle day 12 of a 28-day cycle presents to have an <a class="drug drug_general" data-topicid="8870" href="/d/drug information/8870.html" rel="external">etonogestrel implant</a> placed and reports having intercourse two days previously, during which the partner's condom slipped. If the patient desires oral EC and insertion of the etonogestrel implant, oral EC selection (LNG versus UPA) requires balancing EC efficacy with the patient's desire for immediate versus delayed implant insertion. If immediate implant insertion is prioritized, it is appropriate to provide oral LNG for EC and insert the device as long as the user is willing to accept the small increased risk of pregnancy with LNG compared with UPA and is willing to use abstinence or a barrier method for one week. This approach carries a minimal risk for individuals with a normal body mass index (BMI) who are within 72 hours of UPI. The counseling to use oral LNG for EC would also be appropriate for someone with this history who desires initiation of a combined hormonal method (pills, patch, or ring) or intramuscular <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a>. While UPA is a more effective oral EC method, its use is challenging in this setting because UPA may not be able to block ovulation in the setting of the additional progestin (ie, if the implant is placed at the same time) [<a href="#rid90">90</a>]. If UPA is used in an effort to provide a more effective method of oral EC, then the progestin-containing contraceptive method, in this case the etonogestrel implant, should be initiated more than five days after UPI, which will require an additional visit. In addition, abstinence or a barrier method (condoms) should be used until the new method has been in use for at least one week.</p><p></p><p class="bulletIndent1">There has been hesitancy among clinicians to start long-acting reversible contraceptive methods other than the IUDs following oral LNG, but published data can favorably inform this practice with reported pregnancy risks of approximately 1 percent when oral LNG was provided to women initiating the <a class="drug drug_general" data-topicid="8870" href="/d/drug information/8870.html" rel="external">etonogestrel implant</a>, <a class="drug drug_general" data-topicid="104541" href="/d/drug information/104541.html" rel="external">LNG IUD</a>, or <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> injection [<a href="#rid100">100-102</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Individuals who desire a barrier or pericoital contraceptive</strong> – Barrier contraceptives (female and male condoms) and pericoital contraceptives (diaphragm, spermicidal sponge, cervical cap, or spermicide) do not interfere with oral EC function and can be started immediately. Use of these methods is discussed in detail elsewhere. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/5471.html" rel="external">"Internal (formerly female) condoms"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/5463.html" rel="external">"External (formerly male) condoms"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/3265.html" rel="external">"Pericoital (on demand) contraception: Diaphragm, cervical cap, spermicides, and sponge"</a>.)</p><p></p><p class="headingAnchor" id="H1529445388"><span class="h2">Can oral emergency contraception be a regular contraceptive method?</span><span class="headingEndMark"> — </span>As the efficacy of repeated use of oral EC is generally lower than most contraceptives  (<a class="graphic graphic_figure graphicRef119765" href="/d/graphic/119765.html" rel="external">figure 1</a>), regular use of oral EC is not advised as a contraceptive method. Instead, we counsel patients about all available contraceptives and their use. However, pericoital EC is worthy of consideration for individuals who desire it. This means taking oral LNG immediately before or after each episode of intercourse. A meta-analysis of 11 trials that evaluated 0.75 mg LNG as a pericoital contraceptive reported a pooled Pearl Index of 5.4 pregnancies per 100 woman-years (95% CI 4.1-7.0) [<a href="#rid103">103</a>]. A subsequent study of 321 individuals using 1.5 mg LNG as a pericoital contraceptive (24 hours before or after intercourse) reported, for persons under 35 years of age, a Pearl Index of 10.3 per 100 woman-years (95% CI 5.4-19.9) with typical use and 11 (95% CI 5.7-13.1) for exclusive use [<a href="#rid93">93</a>].</p><p class="headingAnchor" id="H3878180107"><span class="h1">FOLLOW-UP CARE</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Routine counseling</strong> – Patients who use EC can anticipate their period within three weeks of initiating EC [<a href="#rid6">6</a>]. Onset of menses can be earlier or later than usual. Those who do not have a period within three weeks of EC use should perform a pregnancy test. While most do not require a specific follow-up visit, we advise patients to contact the office if they experience heavy bleeding with abdominal pain (concerning for ectopic pregnancy); have a positive pregnancy test; or have any concerns regarding lack of return of menses, bleeding, or any other questions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Do users need a follow-up pregnancy test?</strong> – EC users who do not have menses within three weeks of taking oral EC should take a urine pregnancy test [<a href="#rid6">6</a>]. It is important to inform EC users that taking oral EC will not protect them against future risk of pregnancy from further intercourse in the current menstrual cycle. Those receiving an <a class="drug drug_general" data-topicid="104542" href="/d/drug information/104542.html" rel="external">levonorgestrel</a><strong> </strong>(LNG) 52 mg intrauterine device (IUD) for EC will likely have irregular bleeding and should be informed to check a urine pregnancy test two to four weeks after IUD placement and at any time if pregnancy symptoms are present.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>What if pregnancy occurs anyway?</strong> – It is possible that the pregnancy existed prior to taking EC, the EC failed, or a pregnancy resulted from additional intercourse after using EC. In all of these cases, oral EC has no known adverse effects on pregnancy [<a href="#rid6">6</a>]. Oral EC use has not been associated with congenital anomalies when pregnancy does occur [<a href="#rid104">104,105</a>]. EC use also does not appear to increase the risk of ectopic pregnancy should pregnancy occur. Should a pregnancy occur after IUD EC placement, the IUD should be removed and pregnancy options and counseling should be provided with linkage to desired care for abortion or pregnancy continuation. (See  <a class="medical medical_review" href="/d/html/5422.html" rel="external">"Intrauterine contraception: Management of side effects and complications", section on 'Pregnancy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Does EC use interfere with future fertility?</strong> – Use of oral Ecs does not negatively impact future fertility [<a href="#rid6">6</a>]. In general, the risk of ectopic pregnancy is reduced compared with females not using EC because the risk of pregnancy itself is reduced.</p><p></p><p class="headingAnchor" id="H2917267145"><span class="h1">DRUG INTERACTIONS</span><span class="headingEndMark"> — </span>Medications that induce the cytochrome P450 (CYP450) 3A hepatic enzyme  (<a class="graphic graphic_table graphicRef76992" href="/d/graphic/76992.html" rel="external">table 4</a>) could theoretically reduce <a class="drug drug_general" data-topicid="15626" href="/d/drug information/15626.html" rel="external">ulipristal</a> acetate (UPA) or oral <a class="drug drug_general" data-topicid="104542" href="/d/drug information/104542.html" rel="external">levonorgestrel</a> (LNG) efficacy, but we do not have clinical and pharmacologic data to address this concern [<a href="#rid68">68,80</a>]. However, the manufacturer advises avoiding CYP450 3A inducers, such as <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a>, at the time of UPA administration because the plasma concentration of UPA is reduced [<a href="#rid37">37</a>]. The manufacturer packaging for oral LNG advises that use of <a class="drug drug_general" data-topicid="8731" href="/d/drug information/8731.html" rel="external">efavirenz</a>, rifampin, or the anti-seizure medications <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a> and <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> with LNG EC may reduce the EC efficacy [<a href="#rid39">39</a>]. However, for women taking CYP450 3A enzyme-inducing medication who desire EC, the British National Formulary and the Medicines and Healthcare products Regulatory Agency advise use of 3 mg oral LNG (twice the routine dose), although supporting data for this approach are lacking [<a href="#rid80">80</a>]. Until further data are available to inform clinical care in this situation, a reasonable approach is to double the dose of UPA or oral LNG for individuals using CYP450 3A-inducing medications, which is what the author does in his practice.</p><p>As the efficacy of the copper 380 mm<sup>2</sup> or LNG intrauterine devices (IUDs) is not impacted by hepatic enzyme-inducing medication, these are the preferred EC methods for those who will accept an IUD.</p><p class="headingAnchor" id="H3288613234"><span class="h1">SPECIAL POPULATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adolescents</strong> – Regardless of user age, all EC methods are safe [<a href="#rid69">69</a>]. Adolescents are capable of understanding and interpreting EC labels and instructions and tolerate oral <a class="drug drug_general" data-topicid="104542" href="/d/drug information/104542.html" rel="external">levonorgestrel</a> (LNG) [<a href="#rid106">106,107</a>]. Including EC information and <a class="drug drug_general" data-topicid="15626" href="/d/drug information/15626.html" rel="external">ulipristal</a> acetate (UPA) prescription, if desired, is appropriate family planning guidance for female and male adolescents. Information specific to adolescent patients can be found through the American Academy of Pediatrics document on <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fpediatrics.aappublications.org%2Fcontent%2Fpediatrics%2F144%2F6%2Fe20193149.full.pdf&amp;token=KIGqmCf2bJIXeLlPtFhYENvdqpFURW%2FPW7v%2Bj7hM1HB4JYGHow514rJ%2FI1%2FzZiA8B5yQQvtRO7S3M51byVn2mmauaqU%2Frywf%2BDVdhCLDfUs%3D&amp;TOPIC_ID=5475" target="_blank">Emergency Contraception</a>, 2019.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Breastfeeding individuals</strong> – All EC methods are acceptable for use during lactation [<a href="#rid22">22</a>]. The Centers for Disease Control and Prevention's Medical Eligibility Criteria place no restriction on UPA use for breastfeeding persons, though they recommend expressing and discarding breast milk for 24 hours based on evidence of the drug in the milk of rats. There are no human data regarding infant UPA exposure. LNG passes into breast milk in minimal quantities. There are no contraindications to use of either intrauterine device (IUD) in breastfeeding individuals. (See  <a class="medical medical_review" href="/d/html/6708.html" rel="external">"Contraception: Postpartum counseling and methods", section on 'Impact of contraception on breastfeeding'</a>.)</p><p></p><p class="headingAnchor" id="H923225368"><span class="h1">ISSUES RELATED TO EMERGENCY CONTRACEPTION</span></p><p class="headingAnchor" id="H1053733039"><span class="h2">Evolving complexities of delivering emergency contraception</span><span class="headingEndMark"> — </span>Over the last few years, the clinical approach to EC has become more complicated. New methods have been developed, data have demonstrated decreased efficacy of oral EC methods for users with elevated body mass indices (BMIs), and <a class="drug drug_general" data-topicid="15626" href="/d/drug information/15626.html" rel="external">ulipristal</a> acetate (UPA) may decrease pregnancy protection for those persons starting a method of hormonal contraception along with EC. Constants also persist in this dynamic period. The copper 380 mm<sup>2</sup> intrauterine device (IUD) remains the most effective method of EC and the only form of EC that provides ongoing highly effective contraception without additional action. It also remains true that people know when they need EC and can reliably use it safely. The use of oral EC still does not require a physical examination, pregnancy test, or laboratory tests [<a href="#rid80">80</a>]. Of course, it is still appropriate to offer future contraception to EC users and support for those who seek EC following sexual assault, as well as sensitivity to those who do not wish to discuss it.</p><p class="headingAnchor" id="H894474885"><span class="h2">Availability</span><span class="headingEndMark"> — </span>Regardless of whether patients are directly requesting EC, they have a right to know about it and obtain it, if it can be helpful and they desire it. This includes being informed of the copper 380 mm<sup>2</sup> IUD as the method with greatest efficacy and ability to provide ongoing contraception. However, education by itself is inadequate if the clinician does not have the ability to place IUDs when requested nor have a pathway for referral with same-day insertion for those without IUD insertion experience. Preventing undesired pregnancy is an emergency, as implied by the "E" in "EC" and should be treated accordingly.</p><p>In the United States, despite availability of multiple EC methods, there are a host of obstacles that EC users may encounter. While both brand name and generic forms of oral <a class="drug drug_general" data-topicid="104542" href="/d/drug information/104542.html" rel="external">levonorgestrel</a> (LNG) EC are available over the counter without age or gender restriction, there can be serious challenges to those attempting to obtain it. Research evaluating pharmacy user interactions have reported pharmacies not stocking the medication; keeping this over-the-counter medication in a locked location or behind the counter; employees providing incorrect information about restrictions; and high cost [<a href="#rid108">108,109</a>]. Additionally, UPA requires an interaction with a medical provider to acquire a prescription. A survey of 10 United States cities reported that only 10 percent of pharmacies actually carried UPA, though 72 percent had the ability to order it with a mean wait time of 24 hours [<a href="#rid110">110</a>]. The IUDs have a distinct set of obstacles, including need for a timely in-person visit, provision of a potentially uncomfortable insertion procedure, and the need for a provider capable of placing the device.</p><p class="headingAnchor" id="H1656264652"><span class="h1">RESOURCES FOR PATIENTS AND CLINICIANS</span><span class="headingEndMark"> — </span>The following resources are available in the public domain without cost.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cecinfo.org%2F&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLOceV7A59bVX%2FDTtB42oeVqvALUkLBSw0hah5bEtTSir&amp;TOPIC_ID=5475" target="_blank">International Consortium for Emergency Contraception</a> provides several rigorously reviewed clinical publications by global experts including the definitive Emergency Contraceptive Pills: Medical and Service Delivery Guidance, Fourth Edition, 2018. They also provide country-by-country EC information, client information in several languages, and information on regional consortia (American, Latin American, African, European, and Arab).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.plannedparenthood.org%2F&amp;token=21DvCW7SFWB4fIB0s13CtcAKVdflTh2feipw4VEwaocylraRJrkh43cwEX8GU80r&amp;TOPIC_ID=5475" target="_blank">Planned Parenthood</a> provides resources for patients and clinicians on contraception and reproductive health care.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.bedsider.org%2F&amp;token=h7Ird6MEQJ0ciS3wlIS74wS%2BbqJQEspyaSo36FRNdkGJJnrJaPDlUEGuXmILPu5F&amp;TOPIC_ID=5475" target="_blank">Bedsider.org</a> is an online birth control support network for women ages 18 to 29.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The American College of Obstetricians and Gynecologists – <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.acog.org%2FPatients%2FFAQs%2FEmergency-Contraception&amp;token=ppy6PCRiE9HJgc%2Bl6sW1nYQQUhPspg9gS8wNqU2W9Yjyuwx5AkEHJmBMoDK44CQzzO9lrAg3whiiSTfrkKYhkKsm%2FYIXs1Vin3WHuulpGz0%3D&amp;TOPIC_ID=5475" target="_blank">FAQ 114 Emergency Contraception</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The Faculty of Sexual &amp; Reproductive Healthcare of the Royal College of Obstetricians and Gynaecologists Clinical Guideline – <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.fsrh.org%2Fstandards-and-guidance%2Fdocuments%2Fceu-clinical-guidance-emergency-contraception-march-2017%2F&amp;token=EKC7uAgbQdho9W%2BIunY%2FUjyc5pCf4AgJziZLAp9aHCJvU6pmuNm7vzTA2M7sOn4J7IcajPyqZ6uMUQi4D8U9Jc1zAGyhFwNJ5a1dzUiIGp9b6%2Bt%2Fs66rYnxcFZuDlgFKrwC1JCwUsNIWoeWxLU0oqw%3D%3D&amp;TOPIC_ID=5475" target="_blank">Emergency Contraception</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The Guttmacher Institute provides information on United States <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.guttmacher.org%2Fstate-policy%2Fexplore%2Femergency-contraception&amp;token=9PHEZqwb6cYjs6xpEd1pawSzxmoohSHg6C6C6vK%2B3jfL11xLYGRHvTJ%2BGCSKkcdRQ1xsztJgjr9RiCYJ7V8DqZnOQ%2BMvA2aWb%2F9pxGsK7Zo%3D&amp;TOPIC_ID=5475" target="_blank">laws and policies</a> for EC</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The American Academy of Pediatrics Policy Statement on <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fpediatrics.aappublications.org%2Fcontent%2Fpediatrics%2F144%2F6%2Fe20193149.full.pdf&amp;token=KIGqmCf2bJIXeLlPtFhYENvdqpFURW%2FPW7v%2Bj7hM1HB4JYGHow514rJ%2FI1%2FzZiA8B5yQQvtRO7S3M51byVn2mmauaqU%2Frywf%2BDVdhCLDfUs%3D&amp;TOPIC_ID=5475" target="_blank">Emergency Contraception</a>, 2019</p><p></p><p class="headingAnchor" id="H668905028"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112268.html" rel="external">"Society guideline links: Contraception"</a>.)</p><p class="headingAnchor" id="H3404313084"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15350.html" rel="external">"Patient education: Emergency contraception (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/8398.html" rel="external">"Patient education: Emergency contraception (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H1943182095"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>What is emergency contraception?</strong> – Emergency contraception (EC) refers to products that prevent pregnancy from occurring after an episode of unprotected intercourse (UPI). EC works by disrupting the timing of ovulation or preventing fertilization of an ovulated egg; it is <strong>not</strong> an abortifacient (ie, abortion-inducing drug). (See <a class="local">'What is emergency contraception and how does it work?'</a> above and <a class="local">'Mechanisms of action'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>What are the emergency contraception methods?</strong> – EC methods, in decreasing order of efficacy, include the copper 380 mm<sup>2</sup> intrauterine device (IUD), <a class="drug drug_general" data-topicid="104542" href="/d/drug information/104542.html" rel="external">levonorgestrel</a> (LNG) 52 mg IUD, <a class="drug drug_general" data-topicid="15626" href="/d/drug information/15626.html" rel="external">ulipristal</a> acetate (UPA), oral LNG, and <a class="drug drug_general" data-topicid="10263" href="/d/drug information/10263.html" rel="external">mifepristone</a> (available outside the United States)  (<a class="graphic graphic_table graphicRef120627" href="/d/graphic/120627.html" rel="external">table 1</a>). The other doses of <a class="drug drug_general" data-topicid="104541" href="/d/drug information/104541.html" rel="external">LNG IUDs</a> have not been studied for EC and thus should not be used. (See <a class="local">'What are the emergency contraception methods?'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>How effective is</strong> <strong>emergency contraception? </strong>– When used for EC, the copper 380 mm<sup>2</sup> and LNG 52 mg IUDs result in pregnancy rates of less than 1 percent. The oral medication EC methods UPA, oral LNG, and <a class="drug drug_general" data-topicid="10263" href="/d/drug information/10263.html" rel="external">mifepristone</a> have pregnancy rates of roughly 1 to 3 percent. (See <a class="local">'How effective is emergency contraception at preventing pregnancy?'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Which emergency contraception method should I pick?</strong>– Selection of an EC agent is driven by patient preference but must also consider method characteristics, need for ongoing contraception, method availability, and cost  (<a class="graphic graphic_algorithm graphicRef130902" href="/d/graphic/130902.html" rel="external">algorithm 1</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>IUD emergency contraception selection</strong> – For patients who desire an IUD for EC, we suggest a copper 380 mm<sup>2</sup> IUD or an LNG 52 mg IUD rather than other hormonal IUDs  (<a class="graphic graphic_algorithm graphicRef130902" href="/d/graphic/130902.html" rel="external">algorithm 1</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Lower-dose <a class="drug drug_general" data-topicid="104541" href="/d/drug information/104541.html" rel="external">LNG IUDs</a> have not been studied for use as EC. Both the copper 380 mm<sup>2</sup> and LNG 52 mg IUD are similarly effective, although supporting data for the LNG 52 mg IUD are limited. For individuals with a negative pregnancy test at the time of EC evaluation, the risk of pregnancy following an IUD insertion is low and likely lower than the risk associated with advising a patient to use oral EC followed by a backup contraceptive method and then IUD placement at a future date. Body weight or body mass index (BMI) does not impact the efficacy of either IUD. (See <a class="local">'Intrauterine devices'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Medication emergency contraception selection </strong>– For patients choosing medication EC, we suggest UPA rather than oral LNG (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). UPA is the most effective oral method but requires a prescription and is not stocked by all pharmacies  (<a class="graphic graphic_algorithm graphicRef130902" href="/d/graphic/130902.html" rel="external">algorithm 1</a>). Oral LNG is the less effective oral agent but is available without a prescription and thus should be the easiest to obtain, which makes it a reasonable alternative. There are additional efficacy concerns for oral LNG in individuals with BMI ≥30 kg/m<sup>2</sup>. UPA or oral LNG for EC do not require a routine physical examination, pregnancy test, or laboratory tests. (See <a class="local">'Oral medication emergency contraception methods'</a> above and <a class="local">'Emergency contraception efficacy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Original Yuzpe method of emergency contraception </strong>– Individuals who cannot access one of the EC methods above can use the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.bedsider.org%2Ffeatures%2F88-the-yuzpe-method-effective-emergency-contraception-dating-back-to-the-70s&amp;token=0S1UYpn%2FP0phpQyBKxjL9OygroOq2rcnMiw7V6xylno6DpYM800H8bcU7y%2FM4zm2X6lzoOxDYwkjGlWjdSUSMZlYmOm4IgtrCtI2z7hC91PafjMqmXzIuQxoBU2me0loSMoYl3TsUPl6ebG7p8SFwQ%3D%3D&amp;TOPIC_ID=5475" target="_blank">Yuzpe method</a>, which is two doses of combined oral contraceptives containing the equivalent of 100 to 120 mcg of ethinyl estradiol and 0.5 to 0.6 mg of LNG (or the equivalent) taken 12 hours apart. However, the efficacy of this approach is lower than that of standard EC methods. (See <a class="local">'What are the emergency contraception methods?'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10263" href="/d/drug information/10263.html" rel="external">Mifepristone</a> – Where available, mifepristone 10 mg to 25 mg orally can be used for EC. Limited data suggest its efficacy is at least that of <a class="drug drug_general" data-topicid="104542" href="/d/drug information/104542.html" rel="external">levonorgestrel</a> and greater than that of the Yuzpe method. (See <a class="local">'Oral medication emergency contraception methods'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>When to start contraception</strong>? – The future risk of pregnancy in patients presenting for EC highlights the need for initiating ongoing contraception for those with interest. The timing of contraceptive start and need for backup contraception or abstinence vary with the EC method  (<a class="graphic graphic_algorithm graphicRef130902" href="/d/graphic/130902.html" rel="external">algorithm 1</a> and <a class="graphic graphic_table graphicRef121199" href="/d/graphic/121199.html" rel="external">table 3</a>). (See <a class="local">'When to start contraception after emergency contraception'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>What patient groups or medications require additional consideration with emergency contraception?</strong> – All EC methods are safe for adolescents and lactating individuals. Medications that induce the cytochrome P450 (CYP450) 3A hepatic enzyme  (<a class="graphic graphic_table graphicRef76992" href="/d/graphic/76992.html" rel="external">table 4</a>) could theoretically reduce UPA or LNG efficacy, but we do not have clinical and pharmacologic data to address this concern. (See <a class="local">'Special populations'</a> above and <a class="local">'Drug interactions'</a> above.)</p><p></p><p class="headingAnchor" id="H1724332909"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Mimi Zieman, MD, and Andrew Kaunitz, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Brache V, Cochon L, Deniaud M, Croxatto HB. Ulipristal acetate prevents ovulation more effectively than levonorgestrel: analysis of pooled data from three randomized trials of emergency contraception regimens. Contraception 2013; 88:611.</a></li><li class="breakAll">Decisional Memorandum. New Drug Application 21998, Supplement 5 Levonorgestrel 1.5 mg Tablet Emergency Contraceptive Labeling Supplement for Update to Mechanism of Action Information. US Food and Drug Administration. December 2022. www.accessdata.fda.gov/drugsatfda_docs/label/2022/021998Orig1s005SumR.pdf (Accessed on January 18, 2023).</li><li><a class="nounderline abstract_t">Marions L, Cekan SZ, Bygdeman M, Gemzell-Danielsson K. Effect of emergency contraception with levonorgestrel or mifepristone on ovarian function. Contraception 2004; 69:373.</a></li><li><a class="nounderline abstract_t">Adashi EY, Cohen IG, Wilcox AJ. The FDA Declares Levonorgestrel a Nonabortifacient-A 50-Year Saga Takes a Decisive Turn. JAMA Health Forum 2023; 4:e232257.</a></li><li><a class="nounderline abstract_t">Li HW, Lo SS, Ng EH, Ho PC. Efficacy of ulipristal acetate for emergency contraception and its effect on the subsequent bleeding pattern when administered before or after ovulation. Hum Reprod 2016; 31:1200.</a></li><li class="breakAll">Trussell J, Cleland K, Bimla Schwarz E. Emergency Contraception. In: Contraceptive Technology, 21, Hatcher RA, Nelson AL, Trussell J, Cwiak C, Cason P, Policar MS, Edelman AB, Aiken AR, Marrazzo JM, Kowal D (Eds), Ayer Company Publishers, Inc., New York, NY 2018. p.329-365.</li><li><a class="nounderline abstract_t">Van Look PF, von Hertzen H. Clinical uses of antiprogestogens. Hum Reprod Update 1995; 1:19.</a></li><li><a class="nounderline abstract_t">Gemzell-Danielsson K, Berger C, P G L L. Emergency contraception -- mechanisms of action. Contraception 2013; 87:300.</a></li><li><a class="nounderline abstract_t">Li HWR, Resche-Rigon M, Bagchi IC, et al. Does ulipristal acetate emergency contraception (ella®) interfere with implantation? Contraception 2019; 100:386.</a></li><li><a class="nounderline abstract_t">Noé G, Croxatto HB, Salvatierra AM, et al. Contraceptive efficacy of emergency contraception with levonorgestrel given before or after ovulation. Contraception 2011; 84:486.</a></li><li><a class="nounderline abstract_t">Berger C, Boggavarapu NR, Menezes J, et al. Effects of ulipristal acetate on human embryo attachment and endometrial cell gene expression in an in vitro co-culture system. Hum Reprod 2015; 30:800.</a></li><li><a class="nounderline abstract_t">Ortiz ME, Croxatto HB. Copper-T intrauterine device and levonorgestrel intrauterine system: Biological bases of their mechanism of action. Contraception 2007; 75:S16.</a></li><li class="breakAll">Dean G, Schwarz EB. Intrauterine devices. In: Contraceptive Technology, 21st ed, Trussell J, Cwiak C, Cason P, et al (Eds), Ayer Company Publishers, Inc., New York 2018. p.157.</li><li><a class="nounderline abstract_t">Bylander A, Nutu M, Wellander R, et al. Rapid effects of progesterone on ciliary beat frequency in the mouse fallopian tube. Reprod Biol Endocrinol 2010; 8:48.</a></li><li><a class="nounderline abstract_t">Mahmood T, Saridogan E, Smutna S, et al. The effect of ovarian steroids on epithelial ciliary beat frequency in the human Fallopian tube. Hum Reprod 1998; 13:2991.</a></li><li><a class="nounderline abstract_t">Nutu M, Weijdegård B, Thomas P, et al. Distribution and hormonal regulation of membrane progesterone receptors beta and gamma in ciliated epithelial cells of mouse and human fallopian tubes. Reprod Biol Endocrinol 2009; 7:89.</a></li><li><a class="nounderline abstract_t">Tamburrino L, Marchiani S, Minetti F, et al. The CatSper calcium channel in human sperm: relation with motility and involvement in progesterone-induced acrosome reaction. Hum Reprod 2014; 29:418.</a></li><li><a class="nounderline abstract_t">Black TR, Goldstuck ND, Spence A. Post-coital intrauterine device insertion - a further evaluation. Contraception 1980; 22:653.</a></li><li><a class="nounderline abstract_t">Guillebaud J, Kubba A, Rowlands S, et al. Post-Coital Contraception with Danazol, Compared with an Ethinyloestradiol—Norgestrel Combination or Insertion of an Intra-Uterine Device. J Obstet Gynaecol 1983; 3:S64.</a></li><li><a class="nounderline abstract_t">Cleland K, Zhu H, Goldstuck N, et al. The efficacy of intrauterine devices for emergency contraception: A systematic review of 35 years of experience. Hum Reprod 2012; 27:1994.</a></li><li><a class="nounderline abstract_t">Turok DK, Gero A, Simmons RG, et al. Levonorgestrel vs. Copper Intrauterine Devices for Emergency Contraception. N Engl J Med 2021; 384:335.</a></li><li><a class="nounderline abstract_t">Curtis KM, Tepper NK, Jatlaoui TC, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. MMWR Recomm Rep 2016; 65:1.</a></li><li class="breakAll">Medical eligibility criteria for contraceptive use. World Health Organization. 5th edition. 2015 https://www.who.int/publications/i/item/9789241549158 (Accessed on January 31, 2021).</li><li><a class="nounderline abstract_t">Dunn S, Guilbert É, SOCIAL SEXUAL ISSUES COMMITTEE. Emergency contraception. J Obstet Gynaecol Can 2012; 34:870.</a></li><li class="breakAll">Paragard T 380A (copper) intrauterine device. US Food and Drug Administration (FDA) approved product information. Revised September, 2019. US National Library of Medicine. www.dailymed.nlm.nih.gov (Accessed on February 01, 2021).</li><li><a class="nounderline abstract_t">Turok DK, Jacobson JC, Dermish AI, et al. Emergency contraception with a copper IUD or oral levonorgestrel: an observational study of 1-year pregnancy rates. Contraception 2014; 89:222.</a></li><li><a class="nounderline abstract_t">Long-term reversible contraception. Twelve years of experience with the TCu380A and TCu220C. Contraception 1997; 56:341.</a></li><li class="breakAll">Levonorgestrel 52 mg IUD for Emergency Contraception and Same-Day Start. U.S. National Library of Medicine ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT05444582?term=NCT05444582&amp;draw=2&amp;rank=1 (Accessed on January 17, 2023).</li><li><a class="nounderline abstract_t">Kaiser JE, Turok DK, Gero A, et al. One-year pregnancy and continuation rates after placement of levonorgestrel or copper intrauterine devices for emergency contraception: a randomized controlled trial. Am J Obstet Gynecol 2023; 228:438.e1.</a></li><li class="breakAll">Mirena- levonorgestrel intrauterine device. US Food and Drug Administration (FDA) approved product information. Revised August, 2020. US National Library of Medicine. www.dailymed.nlm.nih.gov (Accessed on February 01, 2021).</li><li><a class="nounderline abstract_t">Rowe P, Farley T, Peregoudov A, et al. Safety and efficacy in parous women of a 52-mg levonorgestrel-medicated intrauterine device: A 7-year randomized comparative study with the TCu380A. Contraception 2016; 93:498.</a></li><li><a class="nounderline abstract_t">McNicholas C, Swor E, Wan L, Peipert JF. Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: 2 years beyond Food and Drug Administration-approved duration. Am J Obstet Gynecol 2017.</a></li><li class="breakAll">LILETTA- levonorgestrel intrauterine device. US Food and Drug Administration (FDA) approved product information. Revised November, 2022. US National Library of Medicine. www.dailymed.nlm.nih.gov (Accessed on November 28, 2022).</li><li><a class="nounderline abstract_t">Diedrich JT, Desai S, Zhao Q, et al. Association of short-term bleeding and cramping patterns with long-acting reversible contraceptive method satisfaction. Am J Obstet Gynecol 2015; 212:50.e1.</a></li><li><a class="nounderline abstract_t">Sanders JN, Myers K, Gawron LM, et al. Contraceptive Method Use During the Community-Wide HER Salt Lake Contraceptive Initiative. Am J Public Health 2018; 108:550.</a></li><li><a class="nounderline abstract_t">Peipert JF, Zhao Q, Allsworth JE, et al. Continuation and satisfaction of reversible contraception. Obstet Gynecol 2011; 117:1105.</a></li><li class="breakAll">Ulipristal acetate. US FDA approved product information. National Library of Medicine. www.dailymed.nlm.nih.gov/dailymed/ (Accessed on March 22, 2019).</li><li><a class="nounderline abstract_t">Hsiang D, Dunn S. Emergency contraception. CMAJ 2016; 188:E536.</a></li><li class="breakAll">Plan B (levonorgestrel). US FDA prescribing information; North Wales, PA: Teva Women’s Health, Inc.; September 2017. (Available online at https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021045s016lbl.pdf). Accesssed March 9, 2019.</li><li><a class="nounderline abstract_t">Piaggio G, Kapp N, von Hertzen H. Effect on pregnancy rates of the delay in the administration of levonorgestrel for emergency contraception: a combined analysis of four WHO trials. Contraception 2011; 84:35.</a></li><li><a class="nounderline abstract_t">Li RHW, Lo SST, Gemzell-Danielsson K, et al. Oral emergency contraception with levonorgestrel plus piroxicam: a randomised double-blind placebo-controlled trial. Lancet 2023; 402:851.</a></li><li><a class="nounderline abstract_t">American College of Obstetricians and Gynecologists. Practice bulletin no. 143: medical management of first-trimester abortion. Obstet Gynecol 2014; 123:676.</a></li><li><a class="nounderline abstract_t">Schreiber CA, Creinin MD, Atrio J, et al. Mifepristone Pretreatment for the Medical Management of Early Pregnancy Loss. N Engl J Med 2018; 378:2161.</a></li><li><a class="nounderline abstract_t">Shen J, Che Y, Showell E, et al. Interventions for emergency contraception. Cochrane Database Syst Rev 2019; 1:CD001324.</a></li><li><a class="nounderline abstract_t">Turok DK, Godfrey EM, Wojdyla D, et al. Copper T380 intrauterine device for emergency contraception: highly effective at any time in the menstrual cycle. Hum Reprod 2013; 28:2672.</a></li><li><a class="nounderline abstract_t">Espinós JJ, Rodríguez-Espinosa J, Senosiain R, et al. The role of matching menstrual data with hormonal measurements in evaluating effectiveness of postcoital contraception. Contraception 1999; 60:243.</a></li><li><a class="nounderline abstract_t">Espinós-Gómez JJ, Senosiain R, Mata A, et al. What is the seminal exposition among women requiring emergency contraception? A prospective, observational comparative study. Eur J Obstet Gynecol Reprod Biol 2007; 131:57.</a></li><li><a class="nounderline abstract_t">Glasier A, Baird D. The effects of self-administering emergency contraception. N Engl J Med 1998; 339:1.</a></li><li><a class="nounderline abstract_t">Raine TR, Harper CC, Rocca CH, et al. Direct access to emergency contraception through pharmacies and effect on unintended pregnancy and STIs: a randomized controlled trial. JAMA 2005; 293:54.</a></li><li><a class="nounderline abstract_t">Walsh TL, Frezieres RG. Patterns of emergency contraception use by age and ethnicity from a randomized trial comparing advance provision and information only. Contraception 2006; 74:110.</a></li><li><a class="nounderline abstract_t">Sander PM, Raymond EG, Weaver MA. Emergency contraceptive use as a marker of future risky sex, pregnancy, and sexually transmitted infection. Am J Obstet Gynecol 2009; 201:146.e1.</a></li><li><a class="nounderline abstract_t">von Hertzen H, Piaggio G, Ding J, et al. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial. Lancet 2002; 360:1803.</a></li><li><a class="nounderline abstract_t">Creinin MD, Schlaff W, Archer DF, et al. Progesterone receptor modulator for emergency contraception: a randomized controlled trial. Obstet Gynecol 2006; 108:1089.</a></li><li><a class="nounderline abstract_t">Glasier AF, Cameron ST, Fine PM, et al. Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis. Lancet 2010; 375:555.</a></li><li><a class="nounderline abstract_t">Dada OA, Godfrey EM, Piaggio G, et al. A randomized, double-blind, noninferiority study to compare two regimens of levonorgestrel for emergency contraception in Nigeria. Contraception 2010; 82:373.</a></li><li><a class="nounderline abstract_t">Glasier A, Cameron ST, Blithe D, et al. Can we identify women at risk of pregnancy despite using emergency contraception? Data from randomized trials of ulipristal acetate and levonorgestrel. Contraception 2011; 84:363.</a></li><li><a class="nounderline abstract_t">Wu S, Godfrey EM, Wojdyla D, et al. Copper T380A intrauterine device for emergency contraception: a prospective, multicentre, cohort clinical trial. BJOG 2010; 117:1205.</a></li><li><a class="nounderline abstract_t">Goldstuck ND. Delayed postcoital IUD insertion. Contracept Deliv Syst 1983; 4:293.</a></li><li><a class="nounderline abstract_t">Moreau C, Trussell J. Results from pooled Phase III studies of ulipristal acetate for emergency contraception. Contraception 2012; 86:673.</a></li><li><a class="nounderline abstract_t">Randomised controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception. Task Force on Postovulatory Methods of Fertility Regulation. Lancet 1998; 352:428.</a></li><li><a class="nounderline abstract_t">Piaggio G, von Hertzen H, Grimes DA, Van Look PF. Timing of emergency contraception with levonorgestrel or the Yuzpe regimen. Task Force on Postovulatory Methods of Fertility Regulation. Lancet 1999; 353:721.</a></li><li><a class="nounderline abstract_t">Sanders JN, Howell L, Saltzman HM, et al. Unprotected intercourse in the 2 weeks prior to requesting emergency intrauterine contraception. Am J Obstet Gynecol 2016; 215:592.e1.</a></li><li><a class="nounderline abstract_t">BakenRa A, Gero A, Sanders J, et al. Pregnancy Risk by Frequency and Timing of Unprotected Intercourse Before Intrauterine Device Placement for Emergency Contraception. Obstet Gynecol 2021.</a></li><li><a class="nounderline abstract_t">Bahamondes L, Faundes A, Sobreira-Lima B, et al. TCu 380A IUD: A reversible permanent contraceptive method in women over 35 years of age. Contraception 2005; 72:337.</a></li><li><a class="nounderline abstract_t">Jensen JT, Lukkari-Lax E, Schulze A, et al. Contraceptive efficacy and safety of the 52-mg levonorgestrel intrauterine system for up to 8 years: findings from the Mirena Extension Trial. Am J Obstet Gynecol 2022; 227:873.e1.</a></li><li><a class="nounderline abstract_t">Schwarz EB, Gerbert B, Gonzales R. Need for emergency contraception in urgent care settings. Contraception 2007; 75:285.</a></li><li><a class="nounderline abstract_t">Turok DK, Gurtcheff SE, Handley E, et al. A pilot study of the Copper T380A IUD and oral levonorgestrel for emergency contraception. Contraception 2010; 82:520.</a></li><li><a class="nounderline abstract_t">Practice Bulletin No. 152: Emergency Contraception. Obstet Gynecol 2015; 126:e1. Reaffirmed 2022.</a></li><li><a class="nounderline abstract_t">Upadhya KK, COMMITTEE ON ADOLESCENCE. Emergency Contraception. Pediatrics 2019; 144.</a></li><li><a class="nounderline abstract_t">Kapp N, Abitbol JL, Mathé H, et al. Effect of body weight and BMI on the efficacy of levonorgestrel emergency contraception. Contraception 2015; 91:97.</a></li><li><a class="nounderline abstract_t">Festin MPR, Peregoudov A, Seuc A, et al. Effect of BMI and body weight on pregnancy rates with LNG as emergency contraception: analysis of four WHO HRP studies. Contraception 2017; 95:50.</a></li><li class="breakAll">National Health and Nutrition Examination Survey. Normal weight, overweight, and obesity among adults aged 20 and over, by selected characteristics: United States, selected years 1988-1994 through 2013-2016. Centers for Disease Control and Prevention 2017. https://www.cdc.gov/nchs/data/hus/2017/058.pdf (Accessed on March 09, 2019).</li><li><a class="nounderline abstract_t">Natavio M, Stanczyk FZ, Molins EAG, et al. Pharmacokinetics of the 1.5 mg levonorgestrel emergency contraceptive in women with normal, obese and extremely obese body mass index. Contraception 2019; 99:306.</a></li><li><a class="nounderline abstract_t">Edelman AB, Cherala G, Blue SW, et al. Impact of obesity on the pharmacokinetics of levonorgestrel-based emergency contraception: single and double dosing. Contraception 2016; 94:52.</a></li><li><a class="nounderline abstract_t">Praditpan P, Hamouie A, Basaraba CN, et al. Pharmacokinetics of levonorgestrel and ulipristal acetate emergency contraception in women with normal and obese body mass index. Contraception 2017; 95:464.</a></li><li><a class="nounderline abstract_t">Edelman AB, Hennebold JD, Bond K, et al. Double Dosing Levonogestrel-Based Emergency Contraception for Individuals with Obesity. Obstet Gynecol 2022.</a></li><li><a class="nounderline abstract_t">Victor A, Odlind V, Kral JG. Oral contraceptive absorption and sex hormone binding globulins in obese women: effects of jejunoileal bypass. Gastroenterol Clin North Am 1987; 16:483.</a></li><li><a class="nounderline abstract_t">Envall N, Groes Kofoed N, Kopp-Kallner H. Use of effective contraception 6 months after emergency contraception with a copper intrauterine device or ulipristal acetate - a prospective observational cohort study. Acta Obstet Gynecol Scand 2016; 95:887.</a></li><li><a class="nounderline abstract_t">ACOG Committee Opinion No. 777: Sexual Assault. Obstet Gynecol 2019; 133:e296.</a></li><li class="breakAll">FSRH Guideline Emergency Contraception. UK: Faculty of Sexual &amp; Reproductive Healthcare; December 2017.</li><li class="breakAll">Emergency Contraception: State Laws and Policies. Guttmacher Institute 2019. https://www.guttmacher.org/state-policy/explore/emergency-contraception (Accessed on March 09, 2019).</li><li><a class="nounderline abstract_t">Curtis KM, Jatlaoui TC, Tepper NK, et al. U.S. Selected Practice Recommendations for Contraceptive Use, 2016. MMWR Recomm Rep 2016; 65:1.</a></li><li><a class="nounderline abstract_t">Thompson I, Sanders JN, Schwarz EB, et al. Copper intrauterine device placement 6-14 days after unprotected sex. Contraception 2019; 100:219.</a></li><li><a class="nounderline abstract_t">Boraas C, Sanders JN, Schwarz EB, et al. Risk of pregnancy with levonorgestrel-releasing intrauterine system placement 6-14 days after unprotected sexual intercourse. Obstet Gynecol 2021.</a></li><li><a class="nounderline abstract_t">Goodman S, Hendlish SK, Reeves MF, Foster-Rosales A. Impact of immediate postabortal insertion of intrauterine contraception on repeat abortion. Contraception 2008; 78:143.</a></li><li><a class="nounderline abstract_t">Bednarek PH, Creinin MD, Reeves MF, et al. Immediate versus delayed IUD insertion after uterine aspiration. N Engl J Med 2011; 364:2208.</a></li><li><a class="nounderline abstract_t">Langston AM, Joslin-Roher SL, Westhoff CL. Immediate postabortion access to IUDs, implants and DMPA reduces repeat pregnancy within 1 year in a New York City practice. Contraception 2014; 89:103.</a></li><li><a class="nounderline abstract_t">Tocce KM, Sheeder JL, Teal SB. Rapid repeat pregnancy in adolescents: do immediate postpartum contraceptive implants make a difference? Am J Obstet Gynecol 2012; 206:481.e1.</a></li><li><a class="nounderline abstract_t">Bergin A, Tristan S, Terplan M, et al. A missed opportunity for care: two-visit IUD insertion protocols inhibit placement. Contraception 2012; 86:694.</a></li><li><a class="nounderline abstract_t">Brache V, Cochon L, Duijkers IJ, et al. A prospective, randomized, pharmacodynamic study of quick-starting a desogestrel progestin-only pill following ulipristal acetate for emergency contraception. Hum Reprod 2015; 30:2785.</a></li><li><a class="nounderline abstract_t">Arowojolu AO, Okewole IA, Adekunle AO. Comparative evaluation of the effectiveness and safety of two regimens of levonorgestrel for emergency contraception in Nigerians. Contraception 2002; 66:269.</a></li><li class="breakAll">CEU Clinical Guidance: Emergency Contraception- December 2017. Faculty of Reproductive and Sexual Healthcare of the Royal College of Obstetricians and Gynaecologists. March 2017. Revised December 2017. www.fsrh.org/standards-and-guidance/current-clinical-guidance/emergency-contraception/ (Accessed on March 27, 2019).</li><li><a class="nounderline abstract_t">Festin MP, Bahamondes L, Nguyen TM, et al. A prospective, open-label, single arm, multicentre study to evaluate efficacy, safety and acceptability of pericoital oral contraception using levonorgestrel 1.5 mg. Hum Reprod 2016; 31:530.</a></li><li class="breakAll">Emergency Contraceptive Pills: Medical and Service Delivery Guidance. International Consortium for Emergency Contraception 2018. https://www.cecinfo.org/wp-content/uploads/2018/12/ICEC-guides_FINAL.pdf (Accessed on March 09, 2019).</li><li><a class="nounderline abstract_t">Garbers S, Bell DL, Ogaye K, et al. Advance provision of emergency contraception to young men: An exploratory study in a clinic setting. Contraception 2018.</a></li><li><a class="nounderline abstract_t">Polis CB, Schaffer K, Blanchard K, et al. Advance provision of emergency contraception for pregnancy prevention (full review). Cochrane Database Syst Rev 2007; :CD005497.</a></li><li><a class="nounderline abstract_t">Fay KE, Clement AC, Gero A, et al. Rates of pregnancy among levonorgestrel and copper intrauterine emergency contraception initiators: Implications for backup contraception recommendations. Contraception 2021; 104:561.</a></li><li><a class="nounderline abstract_t">Glasier A. Starting hormonal contraception after using emergency contraception: what should we recommend? Hum Reprod 2015; 30:2708.</a></li><li class="breakAll">Providing Ongoing Hormonal Contraception after Use of Emergency Contraceptive Pills. American Society for Emergency Contraception 2016. http://americansocietyforec.org/uploads/3/4/5/6/34568220/asec_fact_sheet-_hormonal_contraception_after_ec.pdf (Accessed on March 09, 2019).</li><li><a class="nounderline abstract_t">Turok DK, Sanders JN, Thompson IS, et al. Preference for and efficacy of oral levonorgestrel for emergency contraception with concomitant placement of a levonorgestrel IUD: a prospective cohort study. Contraception 2016; 93:526.</a></li><li><a class="nounderline abstract_t">Richards M, Teal SB, Sheeder J. Risk of luteal phase pregnancy with any-cycle-day initiation of subdermal contraceptive implants. Contraception 2017; 95:364.</a></li><li><a class="nounderline abstract_t">Rickert VI, Tiezzi L, Lipshutz J, et al. Depo Now: preventing unintended pregnancies among adolescents and young adults. J Adolesc Health 2007; 40:22.</a></li><li><a class="nounderline abstract_t">Halpern V, Raymond EG, Lopez LM. Repeated use of pre- and postcoital hormonal contraception for prevention of pregnancy. Cochrane Database Syst Rev 2014; :CD007595.</a></li><li><a class="nounderline abstract_t">Zhang L, Chen J, Wang Y, et al. Pregnancy outcome after levonorgestrel-only emergency contraception failure: a prospective cohort study. Hum Reprod 2009; 24:1605.</a></li><li><a class="nounderline abstract_t">Levy DP, Jager M, Kapp N, Abitbol JL. Ulipristal acetate for emergency contraception: postmarketing experience after use by more than 1 million women. Contraception 2014; 89:431.</a></li><li><a class="nounderline abstract_t">Raine TR, Ricciotti N, Sokoloff A, et al. An over-the-counter simulation study of a single-tablet emergency contraceptive in young females. Obstet Gynecol 2012; 119:772.</a></li><li><a class="nounderline abstract_t">Harper CC, Rocca CH, Darney PD, et al. Tolerability of levonorgestrel emergency contraception in adolescents. Am J Obstet Gynecol 2004; 191:1158.</a></li><li><a class="nounderline abstract_t">Chau VM, Stamm CA, Borgelt L, et al. Barriers to Single-Dose Levonorgestrel-Only Emergency Contraception Access in Retail Pharmacies. Womens Health Issues 2017; 27:518.</a></li><li><a class="nounderline abstract_t">Cleland K, Bass J, Doci F, Foster AM. Access to Emergency Contraception in the Over-the-Counter Era. Womens Health Issues 2016; 26:622.</a></li><li><a class="nounderline abstract_t">Shigesato M, Elia J, Tschann M, et al. Pharmacy access to Ulipristal acetate in major cities throughout the United States. Contraception 2018; 97:264.</a></li></ol></div><div id="topicVersionRevision">Topic 5475 Version 119.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23809278" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Ulipristal acetate prevents ovulation more effectively than levonorgestrel: analysis of pooled data from three randomized trials of emergency contraception regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23809278" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Ulipristal acetate prevents ovulation more effectively than levonorgestrel: analysis of pooled data from three randomized trials of emergency contraception regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15105059" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Effect of emergency contraception with levonorgestrel or mifepristone on ovarian function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37540521" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The FDA Declares Levonorgestrel a Nonabortifacient-A 50-Year Saga Takes a Decisive Turn.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27052501" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Efficacy of ulipristal acetate for emergency contraception and its effect on the subsequent bleeding pattern when administered before or after ovulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27052501" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Efficacy of ulipristal acetate for emergency contraception and its effect on the subsequent bleeding pattern when administered before or after ovulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9080204" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Clinical uses of antiprogestogens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23114735" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Emergency contraception -- mechanisms of action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31351035" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Does ulipristal acetate emergency contraception (ella®) interfere with implantation?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22018122" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Contraceptive efficacy of emergency contraception with levonorgestrel given before or after ovulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25740886" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Effects of ulipristal acetate on human embryo attachment and endometrial cell gene expression in an in vitro co-culture system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17531610" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Copper-T intrauterine device and levonorgestrel intrauterine system: Biological bases of their mechanism of action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17531610" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Copper-T intrauterine device and levonorgestrel intrauterine system: Biological bases of their mechanism of action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20470431" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Rapid effects of progesterone on ciliary beat frequency in the mouse fallopian tube.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9853843" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The effect of ovarian steroids on epithelial ciliary beat frequency in the human Fallopian tube.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19715581" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Distribution and hormonal regulation of membrane progesterone receptors beta and gamma in ciliated epithelial cells of mouse and human fallopian tubes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24430778" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The CatSper calcium channel in human sperm: relation with motility and involvement in progesterone-induced acrosome reaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7214912" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Post-coital intrauterine device insertion - a further evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Post-Coital Contraception with Danazol, Compared with an Ethinyloestradiol—Norgestrel Combination or Insertion of an Intra-Uterine Device</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22570193" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The efficacy of intrauterine devices for emergency contraception: A systematic review of 35 years of experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33503342" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Levonorgestrel vs. Copper Intrauterine Devices for Emergency Contraception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27467196" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : U.S. Medical Eligibility Criteria for Contraceptive Use, 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27467196" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : U.S. Medical Eligibility Criteria for Contraceptive Use, 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22971457" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Emergency contraception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22971457" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Emergency contraception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24332433" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Emergency contraception with a copper IUD or oral levonorgestrel: an observational study of 1-year pregnancy rates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9494767" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Long-term reversible contraception. Twelve years of experience with the TCu380A and TCu220C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9494767" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Long-term reversible contraception. Twelve years of experience with the TCu380A and TCu220C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36427600" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : One-year pregnancy and continuation rates after placement of levonorgestrel or copper intrauterine devices for emergency contraception: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36427600" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : One-year pregnancy and continuation rates after placement of levonorgestrel or copper intrauterine devices for emergency contraception: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26916172" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Safety and efficacy in parous women of a 52-mg levonorgestrel-medicated intrauterine device: A 7-year randomized comparative study with the TCu380A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28147241" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: 2 years beyond Food and Drug Administration-approved duration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28147241" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: 2 years beyond Food and Drug Administration-approved duration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25046805" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Association of short-term bleeding and cramping patterns with long-acting reversible contraceptive method satisfaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29470119" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Contraceptive Method Use During the Community-Wide HER Salt Lake Contraceptive Initiative.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21508749" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Continuation and satisfaction of reversible contraception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21508749" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Continuation and satisfaction of reversible contraception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27821461" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Emergency contraception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27821461" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Emergency contraception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21664508" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Effect on pregnancy rates of the delay in the administration of levonorgestrel for emergency contraception: a combined analysis of four WHO trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37597523" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Oral emergency contraception with levonorgestrel plus piroxicam: a randomised double-blind placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24553166" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Practice bulletin no. 143: medical management of first-trimester abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29874535" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Mifepristone Pretreatment for the Medical Management of Early Pregnancy Loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30661244" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Interventions for emergency contraception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23945595" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Copper T380 intrauterine device for emergency contraception: highly effective at any time in the menstrual cycle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10640171" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The role of matching menstrual data with hormonal measurements in evaluating effectiveness of postcoital contraception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16759787" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : What is the seminal exposition among women requiring emergency contraception? A prospective, observational comparative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9647872" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : The effects of self-administering emergency contraception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15632336" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Direct access to emergency contraception through pharmacies and effect on unintended pregnancy and STIs: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16860048" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Patterns of emergency contraception use by age and ethnicity from a randomized trial comparing advance provision and information only.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19646565" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Emergency contraceptive use as a marker of future risky sex, pregnancy, and sexually transmitted infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12480356" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17077229" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Progesterone receptor modulator for emergency contraception: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20116841" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20851232" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : A randomized, double-blind, noninferiority study to compare two regimens of levonorgestrel for emergency contraception in Nigeria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21920190" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Can we identify women at risk of pregnancy despite using emergency contraception? Data from randomized trials of ulipristal acetate and levonorgestrel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20618314" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Copper T380A intrauterine device for emergency contraception: a prospective, multicentre, cohort clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12265804" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Delayed postcoital IUD insertion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22770793" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Results from pooled Phase III studies of ulipristal acetate for emergency contraception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9708750" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Randomised controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception. Task Force on Postovulatory Methods of Fertility Regulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10073517" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Timing of emergency contraception with levonorgestrel or the Yuzpe regimen. Task Force on Postovulatory Methods of Fertility Regulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27349294" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Unprotected intercourse in the 2 weeks prior to requesting emergency intrauterine contraception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Pregnancy Risk by Frequency and Timing of Unprotected Intercourse Before Intrauterine Device Placement for Emergency Contraception</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16246658" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : TCu 380A IUD: A reversible permanent contraceptive method in women over 35 years of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36096186" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Contraceptive efficacy and safety of the 52-mg levonorgestrel intrauterine system for up to 8 years: findings from the Mirena Extension Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17362707" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Need for emergency contraception in urgent care settings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21074014" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : A pilot study of the Copper T380A IUD and oral levonorgestrel for emergency contraception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26287787" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Practice Bulletin No. 152: Emergency Contraception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31740497" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Emergency Contraception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25528415" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Effect of body weight and BMI on the efficacy of levonorgestrel emergency contraception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27527670" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Effect of BMI and body weight on pregnancy rates with LNG as emergency contraception: analysis of four WHO HRP studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27527670" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Effect of BMI and body weight on pregnancy rates with LNG as emergency contraception: analysis of four WHO HRP studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30703352" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Pharmacokinetics of the 1.5 mg levonorgestrel emergency contraceptive in women with normal, obese and extremely obese body mass index.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27000996" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Impact of obesity on the pharmacokinetics of levonorgestrel-based emergency contraception: single and double dosing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28126541" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Pharmacokinetics of levonorgestrel and ulipristal acetate emergency contraception in women with normal and obese body mass index.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Double Dosing Levonogestrel-Based Emergency Contraception for Individuals with Obesity</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2449395" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Oral contraceptive absorption and sex hormone binding globulins in obese women: effects of jejunoileal bypass.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27109900" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Use of effective contraception 6 months after emergency contraception with a copper intrauterine device or ulipristal acetate - a prospective observational cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30913202" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : ACOG Committee Opinion No. 777: Sexual Assault.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30913202" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : ACOG Committee Opinion No. 777: Sexual Assault.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30913202" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : ACOG Committee Opinion No. 777: Sexual Assault.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27467319" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : U.S. Selected Practice Recommendations for Contraceptive Use, 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31176689" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Copper intrauterine device placement 6-14 days after unprotected sex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Risk of pregnancy with levonorgestrel-releasing intrauterine system placement 6-14 days after unprotected sexual intercourse</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18672116" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Impact of immediate postabortal insertion of intrauterine contraception on repeat abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21651392" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Immediate versus delayed IUD insertion after uterine aspiration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24309218" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Immediate postabortion access to IUDs, implants and DMPA reduces repeat pregnancy within 1 year in a New York City practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22631865" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Rapid repeat pregnancy in adolescents: do immediate postpartum contraceptive implants make a difference?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22770798" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : A missed opportunity for care: two-visit IUD insertion protocols inhibit placement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26405263" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : A prospective, randomized, pharmacodynamic study of quick-starting a desogestrel progestin-only pill following ulipristal acetate for emergency contraception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12413624" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Comparative evaluation of the effectiveness and safety of two regimens of levonorgestrel for emergency contraception in Nigerians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12413624" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Comparative evaluation of the effectiveness and safety of two regimens of levonorgestrel for emergency contraception in Nigerians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26830816" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : A prospective, open-label, single arm, multicentre study to evaluate efficacy, safety and acceptability of pericoital oral contraception using levonorgestrel 1.5 mg.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26830816" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : A prospective, open-label, single arm, multicentre study to evaluate efficacy, safety and acceptability of pericoital oral contraception using levonorgestrel 1.5 mg.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29678366" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Advance provision of emergency contraception to young men: An exploratory study in a clinic setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17443596" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Advance provision of emergency contraception for pregnancy prevention (full review).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34166648" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Rates of pregnancy among levonorgestrel and copper intrauterine emergency contraception initiators: Implications for backup contraception recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26405264" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Starting hormonal contraception after using emergency contraception: what should we recommend?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26405264" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Starting hormonal contraception after using emergency contraception: what should we recommend?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26944863" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Preference for and efficacy of oral levonorgestrel for emergency contraception with concomitant placement of a levonorgestrel IUD: a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28163088" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Risk of luteal phase pregnancy with any-cycle-day initiation of subdermal contraceptive implants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17185202" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Depo Now: preventing unintended pregnancies among adolescents and young adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25259677" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Repeated use of pre- and postcoital hormonal contraception for prevention of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19336440" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Pregnancy outcome after levonorgestrel-only emergency contraception failure: a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24508124" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Ulipristal acetate for emergency contraception: postmarketing experience after use by more than 1 million women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22395146" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : An over-the-counter simulation study of a single-tablet emergency contraceptive in young females.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15507936" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Tolerability of levonorgestrel emergency contraception in adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28442191" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Barriers to Single-Dose Levonorgestrel-Only Emergency Contraception Access in Retail Pharmacies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27682018" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Access to Emergency Contraception in the Over-the-Counter Era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29097224" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Pharmacy access to Ulipristal acetate in major cities throughout the United States.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
